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SuMMARy – These guidelines have been developed to assist the physician in making appro-
priate choices in work-up and treatment of patients with headaches. The specific aim of the evidence 
Based guidelines for treatment of primary headaches – 2012 update is to provide recommendati-
ons for establishing an accurate diagnosis and choose the most appropriate therapy in the group of 
patients with primary headaches, based on a comprehensive review and meta-analysis of scientific 
evidence with regard to treatment possibilities in Croatia. These data are based on our previous 
evidence Based guidelines for treatment of primary headaches published in 2005 and other reco-
mmendations and guidelines for headache treatment. 
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International Headache Society classification 
system (Headache Classification Committee, 
2004)
The second edition of the international head-
ache Society (ihS) classification system was released 
in 20041. Diagnosis of headache disorders should be 
made as accurately as possible according to the follow-
ing classification: 
A. PrimAry heAdAche disorders
l [g43] Migraine 
1.1 [g43.0] Migraine without aura 
1.2 [g43.1] Migraine with aura 
1.2.1 [g43.10] typical aura with migraine   
  headache 
1.2.2 [g43.10] typical aura with non-migraine  
  headache 
1.2.3 [g43.104] typical aura without headache 
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1.2.4 [g43.105] familial hemiplegic migraine   
  (fhM) 
1.2.5 [g43.105] Sporadic hemiplegic migraine
1.2.6 [g43.103] Basilar-type migraine 
1.3 [g43.82] Childhood periodic syndromes  
  that are commonly precursors of  
  migraine 
1.3.1 [g43.82] Cyclic vomiting 
1.3.2 [g43.820] Abdominal migraine 
1.3.3 [g43.821] Benign paroxysmal vertigo of   
  childhood 
1.4 [g43.81] Retinal migraine 
1.5 [g43.3] Complications of migraine 
1.5.1 [g43.3]  Chronic migraine 
1.5.2 [g43.2]  Status migrainosus 
1.5.3 [g43.3]  persistent aura without in-
farction 
1.5.4 [g43.3]  Migrainous infarction 
1.5.5 [g43.3]   Migraine-triggered seizure 
1.6 [g43.83 probable migraine
1.6.1 [g43.83] probable migraine without aura 
1.6.2 [g43.83] probable migraine with aura 
1.6.5 [g43.83] probable chronic migraine 
2 [g44.2] tension-type headache (tth) 
2.1 [g44.2] infrequent episodic tension-type  
  headache 
2.1.1 [g44.20] infrequent episodic tension-type  
  headache associated with   
  pericranial tenderness 
2.1.2 [g44.21] infrequent episodic tension-type  
  headache not associated with   
  pericranial tenderness 
2.2 [g44.2] frequent episodic tension-type  
  headache
2.2.1 [g44.20] frequent episodic tension-type  
  headache associated with   
  pericranial tenderness 
2.2.2 [g44.21] frequent episodic tension-type  
  headache not associated with   
  pericranial tenderness 
2.3 [g44.2] Chronic tension-type headache 
2.3.1 [g44.22] Chronic tension-type headache  
  associated with pericranial   
  tenderness 
2.3.2 [g44.23] Chronic tension-type headache  
  not associated with pericranial  
  tenderness 
2.4 [g44.28] probable tension-type headache 
2.4.1 [g44.28] probable infrequent episodic   
  tension-type headache
2.4.2 [g44.28] probable frequent episodic   
  tension-type headache 
2.4.3 [g44.28] probable chronic tension-type   
  headache
3 [g44.0] Cluster headache and other 
  trigeminal autonomic    
  cephalalgias 
3.1 [g44.0] Cluster headache 
3.1.1 [g44.01]  episodic cluster headache 
3.1.2 [g44.02]  Chronic cluster headache 
3.2 [g44.03] paroxysmal hemicrania 
3.2.1 [g44.03]  episodic paroxysmal   
   hemicrania 
3.2.2 [g44.03]  Chronic paroxysmal   
   hemicrania (Cph) 
3.3 [g44.08] Short-lasting unilateral 
  neuralgiform headache 
  attacks with     
   Conjunctival injection and   
   tearing (SunCt). 
3.4 [g44.08] probable trigeminal autonomic  
  cephalalgia 
3.4.1 [g44.08]  probable cluster headache 
3.4.2 [g44.08]  probable paroxysmal   
   hemicrania
3.4.3 [g44.08]  probable SunCt
4 [g44.80] other primary headaches 
4.1 [g44.800]  primary stabbing headache 
4.2 [g44.803]  primary cough headache 
4.3 [g44.804]  primary exertional headache 
4.4 [g44.805]  primary headache associated  
   with sexual activity 
4.4.1 [g44.805]  preorgasmic headache 
4.4.2 [g44.805]  orgasmic headache 
4.5 [g44.80]  hypnic headache 
4.6 [g44.80]  primary thunderclap   
   headache 
4.7 [g44.80]  hemicrania continua 
4.8 [g44.2]  new daily-persistent head-
ache (nDph)
B. secondAry heAdAche disorders 
5 [g44.88] headache attributed to head   
  and/or neck trauma 
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6  [g44.81]  headache attributed to cranial or  
  cervical vascular disorder
7 [g44.82] headache attributed to non-  
  vascular intracranial disorder 
8 [g44.4 or g44.83]   headache attributed to a  
        substance or its 
        withdrawal 
9 [g44.821]  headache attributed to infection 
10 [g44.882] headache attributed to disorder  
  of homeostasis 
11 [g44.84] headache or facial pain 
  attributed to disorder of cranium,
  neck,  eyes, ears, nose, sinuses, 
  teeth, mouth or other facial or   
  cranial structures
12 (R 51) headache attributed to   
  psychiatric disorder 
13 [g44.847,  Cranial neuralgias
 g44.848 or  and central causes of facial pain
 g44.85]       
14 [R51] other headache, cranial 
  neuralgia, central or primary   
  facial pain 
introduction
These guidelines have been developed to assist the 
physician in making appropriate choices in the work-
up and treatment of patients with headaches. head-
ache disorders pose a public-health problem with an 
impact on both individuals and society. The socioeco-
nomic burden includes costs associated with health 
care utilization and cost due to sick leave or reduced 
productivity. A large proportion of headache sufferers 
are never diagnosed or regularly treated. 
The primary headache disorders, which include 
migraine and tension-type headache, account for the 
majority of headaches; those with underlying pathol-
ogy are by far less common (tumor, giant cell arteritis, 
aneurysm)2. once the diagnosis has been established, 
acute treatment should be instituted. if the patient has 
a history of recurrent headaches, a plan for treatment 
(acute and/or prophylactic) needs to be established.
The specific aim of the guidelines 2012 update 
is to provide recommendations for establishing an ac-
curate diagnosis and for choosing the most appropri-
ate therapy in the group of primary headache patients, 
based on a comprehensive review and meta-analysis of 
scientific evidence with regard to treatment possibili-
ties in Croatia. These data are based on our previously 
published evidence Based guidelines for treatment 
of primary headaches from 20053 and other recom-
mendations and guidelines for headache treatment.
oVerVieW, diAGnosis And 
cLAssiFicATion
General rules for classification 
Classification of a headache disorder requires the 
following rules to be applied4:
1. to make a diagnosis, all diagnostic criteria must 
be fulfilled. physicians must diagnose or exclude sec-
ondary headaches and diagnose the specific form of 
primary headache.
2. if one headache type fits the diagnostic criteria 
for different categories of headache, then code it in the 
first headache category in the classification for which 
the criteria are fulfilled.
3. if the patient has more than one headache dis-
order, all should be diagnosed in the order of impor-
tance indicated by the patient.
4. if the patient has a form of headache that fulfills 
one set of diagnostic criteria, similar episodes that do 
not quite satisfy the criteria also usually occur. This 
can be due to treatment, lack of ability to remember 
symptoms exactly, and other factors. Ask the patient 
to describe a typical untreated attack or an unsuc-
cessfully treated attack, and ascertain that there have 
been enough of these attacks to establish the diag-
nosis. Then, estimate the days per year with this type 
of headache, adding treated attacks and less typical 
attacks.
5. A major obstacle to an exact diagnosis is reli-
ance on the patient’s history to determine whether the 
criteria are met. in less clear cases, have the patient 
record the attack characteristics prospectively, using a 
headache diary, before the diagnosis is made.
6. patients who develop a particular form of head-
ache for the first time in close temporal relation to the 
onset of one of the disorders listed in groups 5-11 are 
coded to these groups. however, a causal relationship 
is not necessarily indicated. preexisting migraine, ten-
sion type headache, or cluster headache aggravated in 
close temporal relation to one of the disorders listed in 
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groups 5-11 are still coded as migraine, tension-type 
headache, or cluster headache (groups 1-3). 
criteria for hospitalization 
general criteria for urgent and non-urgent admis-
sion are as follows5:
i emergency or urgent admission
1. Medical emergency presenting with a severe head-
ache.
2. Severe headache associated with intractable nausea 
and vomiting producing dehydration or postural 
hypotension, or unable to retain oral medication 
and unable to be controlled in an outpatient set-
ting.
3. failed outpatient treatment of an exacerbation of 
episodic headache disorder with failure to respond 
to “rescue” or backup medications.
4. Certain migraine variants (e.g., hemiplegic mi-
graine, suspected migrainous infarction, basilar 
migraine with serious neurologic symptoms such 
as syncope, confusional migraine, etc.)
a) when a diagnosis has not been established dur-
ing a previous similar occurrence 
b) when established outpatient treatment plan has 
failed
5. Diagnostic suspicion of infectious disorder involv-
ing central nervous system (CnS) (e.g., brain ab-
scess and meningitis) with initiation of appropriate 
diagnostic testing.
6. Diagnostic suspicion of acute vascular compromise 
(e.g., aneurysm, subarachnoid hemorrhage (SAh), 
and carotid dissection) with initiation of appropri-
ate diagnostic testing.
7. Diagnostic suspicion of a structural disorder caus-
ing symptoms requiring an acute setting (e.g., 
brain tumor, increased intracranial pressure) with 
initiation of appropriate diagnostic testing.
8. low cerebrospinal fluid (CSf) headache when an 
outpatient blood patch has failed and an outpatient 
treatment plan has failed.
ii non-emergency admission
1. impaired daily functioning (e.g., many lost days at 
work or school due to headache, threatened rela-
tionships, etc.), with failure to respond to 2 days of 
outpatient treatment with iv. analgesics
2. Severe chronic daily headaches involving chronic 
medication overuse when there is 
a) daily use of potent opioids and/or barbiturates
b) daily use of triptans, simple analgesics, or er-
gotamine in a patient with a documented failed 
trial of withdrawal of these medications
3. Coexistent psychiatric disease documented by 
psychological or psychiatric evaluation with suffi-
cient severity of illness such that a failure to admit 
could pose a health risk to the patient or impair the 
implementation of outpatient treatment.
4. Coexistent or risk of disease (e.g., unstable angina, 
unstable diabetes, recent transient ischemic at-
tack, myocardial infarction in the past 6 months, 
renal failure, hypertension, age >65) necessitating 
monitoring for treatment of headache significant 
enough to warrant admission
diagnostic work-up in patients with headache
i detailed history
Assessment of the headache characteristics re-
quires determination of the following:
•	 temporal profile: 
o time from onset to peak 
o usual time of onset (season, month, menstrual 
cycle, week, hour of day) 
o frequency 
o Duration 
o Stable or changing over past 6 months and life-
time
•	 Descriptive characteristics (pulsatile, throbbing, 
pressing, sharp, etc.) 
•	 location (uni- or bilateral, changing sides) 
•	 Severity 
•	 precipitating features 
•	 Aggravating factors 
•	 factors which relieve the headache 
•	 pharmacological and non-pharmacological treat-
ments which are effective or ineffective 
•	 Aura (present in approximately 15% of migraine 
patients) 
•	 functional disabilities at work, school, housework 
or leisure activities during the past 3 months (in-
formally or using well-validated disability ques-
tionnaire).
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ii neuroimaging 
Detection of treatable lesions remains the primary 
reason to obtain neuroimaging studies6,7. neuroim-
aging may as well relieve the patient’s anxiety about 
having an underlying pathologic condition; therefore 
neuroimaging may improve patient overall satisfac-
tion and medical care. 
in adult patients with recurrent headaches defined 
as migraine, including those with visual aura, with no 
recent change in headache pattern, no history of sei-
zures, and no other focal neurologic signs or symptoms, 
the routine use of neuroimaging is not warranted. in 
patients with atypical headache patterns, a history of 
seizures or focal neurologic signs and symptoms, com-
puterized tomography (Ct) or magnetic resonance im-
aging (MRi) may be indicated. neuroimaging should 
be considered when risk factors for intracranial pathol-
ogy exist. testing should be avoided if it will not lead 
to change in the management. testing that normally 
may not be recommended as a population-policy may 
make sense at an individual level (exceptions may be 
considered for patients who are disabled by their fear of 
serious pathology, or for whom the physician in charge 
is suspicious even in the absence of known predictors of 
abnormalities on neuroimaging studies6,7. 
neurological examination
An abnormal neurological examination increases 
the likelihood of finding significant intracranial pa-
thology (brain tumor, arterio-venous malformation 
(AvM), hydrocephalus) on neuroimaging. The ab-
sence of any abnormalities on neurological examina-
tion reduces the odds of finding a significant abnor-
mality on imaging.
Recommendation: neuroimaging should be con-
sidered in patients with non-acute headache and an 
unexplained abnormal finding on neurological exami-
nation (level B)
neurological symptoms
headache worsened by valsalva maneuver, head-
ache causing awakening from sleep, new headache in 
elderly population, or progressively worsening head-
ache may indicate a higher likelihood of significant 
intracranial pathology. in general, the absence of 
signs and symptoms is less reliable and informative 
than their presence.
Recommendation: evidence is insufficient to make 
specific recommendations regarding neuroimaging 
in the presence or absence of neurological symptoms 
(level C).
reasons to consider neuroimaging for headaches 
Temporal profile and headache features
1. The “first or worst” headache
2. Subacute headache with increased frequency or se-
verity
3. A progressive or new daily persistent headache
4. Chronic daily headache
5. headache always on the same side
6. headache not responding to treatment
7. history of headache causing awakening from 
sleep
demographics
1. new-onset headache in a patient who has cancer 
or is positive for human immunodeficiency virus 
(hiv)
2. new onset headache after age 50
3. patients with headaches and seizures
Associated symptoms and signs
1. headache associated with symptoms and signs 
such as fever, stiff neck, nausea, vomiting
2. headaches other than migraine with aura associ-
ated with focal or generalized neurologic symp-
toms and signs
3. headaches associated with papilledema, cognitive 
impairment, personality change or seizures
effectiveness of cT vs. mri
finding: MRi appears to be more sensitive in 
finding white matter lesions and developmental ve-
nous abnormalities than Ct, a result that could be ex-
pected based upon the characteristics of the two tech-
nologies. The greater resolution and discrimination of 
MRi appears to be of little clinical importance in the 
evaluation of patients with non-acute headache. Data 
are lacking comparing enhanced with unenhanced 
Ct scan.
Recommendation: data are insufficient to make 
any evidence-based recommendations regarding the 
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relative sensitivity of MRi compared with Ct in the 
evaluation of migraine or other non-acute headache 
(level C). 
Which patients with headache require neuroimag-
ing in emergency department? 
patients presenting to emergency department with 
headache and abnormal findings on neurological ex-
amination (i.e. focal deficit, altered mental status, and 
altered cognitive function) should undergo emergent* 
non-contrast head Ct scan. hiv positive patients 
with a new type of headache should be considered 
for an urgent* neuroimaging study. patients present-
ing with acute sudden-onset headache should be con-
sidered for an emergent* head computed tomography 
scan5,6 (level B). patients who are older than 50 years 
presenting with a new type of headache without ab-
normal findings on neurological examination should 
be considered for an urgent neuroimaging study (lev-
el C).
*emergent studies are those essential for a timely decision 
regarding potentially life-threatening or severely disabling 
entities.
*urgent studies are those that are arranged prior to dis-
charge from the emergency department (scan appointment 
is included in disposition) or performed prior to disposition 
when follow-up cannot be assured.
iii electroencephalography
electroencephalography (eeg) is not indicated 
in the routine evaluation of headache. This does not 
exclude the use of eeg to evaluate headache patients 
with associated symptoms suggesting a seizure disor-
der such as atypical migrainous aura or episodic loss 
of consciousness. Assuming head imaging capabilities 
are readily available, eeg is not recommended to ex-
clude a structural cause of headache6 (level C).
iV Lumbar puncture 
lumbar puncture is indicated in the evaluation of:
•	 meningitis, encephalitis
•	 meningeal carcinomatosis or lymphomatosis
•	 SAh (when Ct scan is negative)
•	 high (benign intracranial hypertension) or low 
CSf pressure 
Adult patients with headache exhibiting signs of 
increased intracranial pressure including papilledema, 
absent venous pulsations on funduscopic examina-
tion, altered mental status, or focal neurologic deficits 
should undergo a neuroimaging study before having 
lumbar puncture. in the absence of findings sugges-
tive of increased intracranial pressure, lumbar punc-
ture can be performed without obtaining a neuroim-
aging study6. (note: lumbar puncture does not assess 
for all causes of a sudden severe headache) (level C).
V Angiography 
patients with thunderclap headache who have 
negative findings on head Ct scan, normal open-
ing pressure, and negative findings in CSf analysis 
do not need emergent angiography and can be dis-
charged from emergency department with follow-up 
arranged with their primary care provider or neurolo-
gist6 (level C).
Vi Laboratory studies 
Routine clinical laboratory studies followed by 
specific laboratory studies are recommended if indi-
cated5. 
Diagnostic alarms in the evaluation of headache 
disorders 
patient history or certain signs and symptoms 
should alert the physician in the evaluation of a head-
ache disorder5:
1 migraine 
Migraine is a common neurologic disorder that 
results in a spectrum of disability within and among 
different individuals. Migraine causes significant bur-
den for both the individual and the society. Calcula-
tions of direct costs generally include physician visits, 
emergency department treatment, inpatient care and 
pharmacotherapy. indirect costs include lost work 
days and reduced performance at work; two-thirds of 
the financial burden is linked to indirect costs7. Ap-
proximately three fourths of migraine sufferers have a 
reduced ability to function during attacks with more 
than half reporting severe disability or need for bed 
rest. Most migraine sufferers have not been officially 
diagnosed by a physician; therefore, many patients are 
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lacking medical guidance to effectively address their 
migraine attacks. over half of all migraine suffer-
ers deny having received a migraine diagnosis from 
a physician, and of those patients who receive an ac-
curate diagnosis, many do not receive appropriate 
therapy. prevalence estimates for women range from 
12.9% to 17.6%; the range for men is 3.4%-6.1%8-11. A 
prevalence study was carried out in a Croatian pop-
ulation in 2006: the 1-year crude prevalence of mi-
graine without and with aura in this study was 7.5%, 
of probable migraine 11.3%, and of tth 21.2%. The 
1-year age- and sex-adjusted prevalence of migraine 
was 6.2%, of probable migraine 8.8%, and of tth 
20.7%; the prevalence of migraine combined with 
probable migraine was 15.0%. total crude prevalence 
of headache (combination of migraine, probable mi-
graine and tth) was 39.9%12.
Migraine is consistently found to be more preva-
lent in females than in males, with a female to male 
ratio ranging from 2:1 to 3:1. Migraine prevalence has 
also been found to be age-dependent. in women, the 
prevalence appears to increase with age until the peak 
prevalence is reached during the fourth or fifth de-
cade. A similar trend is seen in males, although the 
peak prevalence occurs earlier. Thereafter, the preva-
lence decreases for both genders but remains higher in 
women than in men. 
Migraine prevalence is significantly higher in Cau-
casians (20.4%) than in African Americans (16.2%) or 
Asian Americans (9.2%)13.
The mechanism of migraine pain development is 
not fully understood. Migraine was initially consid-
ered a cerebrovascular condition, then a neuroinflam-
matory process, and now primarily a neurogenic dis-
 Symptoms    Suspected diagnosis   
•	 headache begins after age 50 – temporal arteritis, mass lesion
•	 Sudden onset headache – SAh, pituitary apoplexy, bleed into a mass or AvM, 
     mass lesion (especially posterior fossa)
•	 Accelerating pattern of headaches  – Mass lesion, subdural hematoma, medication overuse
•	 new onset headache in patient
 with cancer or hiv – Meningitis (chronic or carcinomatous), brain abscess (including  
     toxoplasmosis), metastasis
•	 headache with systemic illness – Meningitis, encephalitis, lyme disease, systemic infection,  
   collagen vascular disease
•	 focal or generalized neurologic 
 symptoms or signs of disease              – Mass lesion, AvM, stroke, collagen vascular disease
•	 papilledema – Mass lesion, pseudotumor, meningitis
order. Migraine is a polygenic multifactorial disorder; 
it seems likely that a combination of genetic factors 
interact with environmental triggers to produce mi-
graine in susceptible patients. The genetic discover-
ies are the latest step in the evolution of our under-
standing of migraine revealing that ion channels and 
transporter mutations may be causative of migraine. 
A gene for familial hemiplegic migraine has been 
mapped to chromosome 19 in most families. The ge-
netics of the more frequent variants, migraine with 
and without aura, is more complex14. genetic and epi-
demiological evidence suggest that changes in blood 
vessels, hypoperfusion disorders and microemboliza-
tion can cause neurovascular dysfunction and evoke 
cortical spreading depression15-18. 
diagnostic testing 
There are, as yet, no tests that confirm the diagno-
sis of migraine5,19-21. The headache diary is the most 
important diagnostic tool and should be filled in for at 
least 3 months, in which the frequency, duration and 
intensity of migraine attacks are recorded. The total 
number of hours with headache per month, presence 
of accompanying symptoms, and use of symptomatic 
therapy should be listed22. Selective testing, including 
neuroimaging (Ct or MRi), eeg, lumbar puncture, 
CSf and blood studies may be indicated to evaluate 
for secondary headache if the causes of concern have 
been identified in patient history or physical examina-
tion. Diagnosis may be complicated if several head-
ache types coexist in the same patient.
neuroimaging is unlikely to reveal an abnormality 
on MRi or Ct scanning in patients with migraine and 
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normal neurological examination6,20,21. neuroimaging 
is not usually warranted for patients with migraine 
and normal neurological examination (level B). for 
patients with atypical headache features or patients 
who do not fulfill the strict definition of migraine (or 
have some additional risk factors), a lower threshold 
for neuroimaging may be applied (level C). 
migraine types
1.1 migraine without aura – diagnostic criteria
Previously used terms: common migraine
A. At least 5 attacks fulfilling B-D
B. headache lasting 4 to 72 hours (untreated or un-
successfully treated)
C. headache has at least two of the following charac-
teristics:
1. unilateral location 
2. pulsating quality
3. moderate or severe intensity (inhibits or pro-
hibits daily activities)
4. aggravation by walking stairs or similar routine 
physical activity
D. During headache, at least one of the following:
1. nausea and/or vomiting
2. photophobia and phonophobia 
e. not attributed to another disorder
1.2 migraine with aura – diagnostic criteria
Previously used terms: classic migraine, hemiplegic 
migraine, hemiparesthetic migraine, aphasic migraine, 
migraine accompagnée
The migraine headache may be preceded by aura; 
approximately 10%-25% of migraine sufferers report 
aura5,11. Aura is a focal neurologic deficit that usually 
precedes the onset of headache by 5-60 minutes. Aura 
is both more sensitive and specific than premonitory 
symptoms in the diagnosis of migraine. 
Aura symptoms:
visual: scotoma; photopsia or phosphenes; geo-
metric forms; fortification spectra; objects may rotate, 
oscillate, or shimmer; brightness appears often very 
bright
visual hallucinations or distortions: metamor-
phopsia; macropsia; zoom or mosaic vision
Sensory: paresthesias, often migrating, often last-
ing for minutes (cheiro-oral), and can become bilat-
eral, olfactory hallucinations 
Motor: weakness or ataxia 
language: dysarthria or aphasia
Delusions and disturbed consciousness: deja vu, 
multiple conscious trance-like states
A. There have been at least two attacks fulfilling cri-
terion B listed below
B. At least three of the following characteristics are 
present:
1. there are one or more fully reversible aura 
symptoms indicating focal cerebral cortical or 
brain stem dysfunction
2. either at least one aura symptom develops grad-
ually over more than 4 minutes, or two or more 
symptoms occur in succession
3. no aura symptom lasts for more than 60 min-
utes; if more than one aura symptom is present, 
accepted duration is proportionally increased
4. headache follows aura with a free interval of 
less than 60 minutes (it may also begin before 
or simultaneously with the aura)
C. no evidence of organic disease-history, physical 
examination and diagnostic tests exclude a sec-
ondary cause
1.2.1 typical aura with migraine headache
A. At least 2 attacks fulfilling criteria B-D
B. Aura consisting of at least one of the following but 
no motor weakness:
l. fully reversible visual symptoms including pos-
itive features (flickering lights, spots or lines) 
and/or negative features (loss of vision)
2. fully reversible sensory symptoms including 
positive symptoms (pins and needles) and /or 
negative features (numbness) 
3. fully reversible dysphasic speech disturbances
A. At least two of the following:
1. homonymous visual symptoms and/or unilat-
eral sensory symptoms
2. at least one aura symptom develops gradually 
over >5 minutes and/or different aura symp-
toms occur in succession over >5 minutes
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3. each symptom lasts >5 and <60 minutes
D. headache fulfilling criteria B-D for 1.1 Migraine 
without aura begins during the aura or follows aura 
within 60 minutes
e. not attributed to another disorder
1.2.2 typical aura with non-migraine headache
A, B, C as in 1.2.1. 
D. headache not fulfilling criteria B-D for 1.1 Mi-
graine without aura begins during the aura or fol-
lows aura within 60 minutes
e. not attributed to another disorder
1.2.3 typical aura without headache
A, B, C as in 1.2.1. 
D. headache does not occur during aura nor follows 
aura within 60 minutes
e. not attributed to another disorder
1.2.4 familial hemiplegic migraine (fhM) (1, 17a)
A. At least 2 attacks fulfilling criteria B and C
B. Aura consisting of fully reversible motor weakness 
and at least one of the following:
l.  fully reversible visual symptoms including pos-
itive features (flickering lights, spots or lines) 
and/or negative features (loss of vision)
2. fully reversible sensory symptoms including 
positive symptoms (pins and needles) and /or 
negative features (numbness) 
3. fully reversible dysphasic speech disturbances
C. At least two of the following:
1. at least one aura symptom develops gradually 
over >5 minutes and/or different aura symp-
toms occur in succession over >5 minutes
2. each aura symptom lasts >5 minutes and <24 
hours
3. headache fulfilling criteria B-D for 1.1. Mi-
graine without aura begins during the aura or 
follows the onset of aura within 60 minutes
D. At least one first- or second-degree relative has at-
tacks fulfilling these criteria A-e
e. not attributed to another disorder
Comment:
•	 in fhM 1 there are mutations in the calcium-
channel gene CACnA1A on chromosome 19, and 
in fhM 2 on chromosome 1. fhM is the only 
known autosomal dominant subtype of migraine
•	 during fhM 1 attacks, disturbances of conscious-
ness (sometimes including coma), fever, CSf pleo-
cytosis and confusion can occur; attacks can be 
triggered by mild trauma
•	 fhM is very often mistaken for epilepsy (and un-
successfully treated as such)
1.2.5 Sporadic hemiplegic migraine
A, B, C as in 1.2.4.
D. no first- or second-degree relative has attacks ful-
filling these criteria A-e
e. not attributed to another disorder
1.2.6 Basilar-type migraine
A. At least 2 attacks fulfilling criteria B-D
B. Aura consisting of at least two of the following 
fully reversible symptoms, but no motor weak-
ness:
1. Dysarthria
2. vertigo
3. tinnitus
4. hypacusia
5. Diplopia
6. visual symptoms simultaneously in both tem-
poral and nasal fields of both eyes
7. Ataxia
8. Decreased level of consciousness
9. Simultaneously bilateral paresthesias
C. At least one of the following:
1. at least one aura symptom develops gradually 
over >5 minutes and/or different aura symp-
toms occur in succession over >5 minutes
2. each aura symptom lasts >5 and <60 minutes
D. headache not fulfilling criteria B-D for 1.1 Mi-
graine without aura begins during the aura or fol-
lows aura within 60 minutes
e. not attributed to another disorder
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Comment
•	 basilar-type migraine should be diagnosed only 
when no motor weakness occurs, since familial 
hemiplegic migraine has basilar-type symptoms in 
60% of cases. 
1.3 childhood periodic syndromes 
Childhood periodic syndromes will not be dis-
cussed in these guidelines.
1.4 retinal migraine – diagnostic criteria
A. At least 2 attacks fulfilling criteria B and C
B. fully reversible monocular positive and/or nega-
tive visual phenomena (scintillations, scotomata or 
blindness) confirmed by examination during attack 
or (after proper instruction) by the patient’s draw-
ing of a monocular field defect during an attack
C. headache fulfilling criteria B-D for 1.1 Migraine 
without aura begins during visual symptoms or 
follows them within 60 minutes
D. normal ophthalmological examination between 
attacks
e. not attributed to another disorder
1.5 complications of migraine – diagnostic criteria
1.5.1 Chronic migraine
A. headache fulfilling criteria C and D for 1.1. Mi-
graine without aura on >15 days/month for >3 
months
B. not attributed to another disorder
Comment:
•	 when medication overuse is present, this is the 
most likely cause of chronic symptoms
1.5.2 Status migrainosus
The ihS defines status migrainosus as an attack of 
migraine in which the headache phase lasts for more 
than 72 hours whether treated or not. The headache 
is continuous throughout the attack or is interrupted 
by the headache-free intervals that last less than 4 
hours. Short-lasting relief due to medication is also 
disregarded. 
A. The present attack in a patient with 1.1. Migraine 
without aura is typical of previous attacks except 
for its duration
B. headache has both of the following features:
1. unremitting for >72 hours
2. severe intensity
C. not attributed to another disorder
Comment
•	 non-debilitating attacks lasting >72 hours but oth-
erwise meeting these criteria are coded as 1.6.1 
probable migraine without aura
1.5.3 persistent aura without infarction
Aura symptoms persisting for more than 1 week 
without radiographic evidence of infarction
A. The present attack in a patient with 1.2. Migraine 
with aura is typical of previous attacks except that 
one or more aura symptoms persist for >1 week
B. not attributed to another disorder
Comment:
•	 persistent	 aura	 symptoms	 are	 often	 bilateral	 and	
may last for months or years
•	 exclude	 posterior	 leukoencephalopathy	 and	 mi-
grainous infarction by MRi
1.5.4 Migrainous infarction
A. The present attack in a patient with 1.2. Migraine 
with aura is typical of previous attacks except that 
one or more aura symptoms persist for >60 min-
utes
B. neuroimaging demonstrates ischemic infarction in 
a relevant area
C. not attributed to another disorder
Comment:
•	 only cerebral infarction occurring during the 
course of a typical migraine with aura attack ful-
fills the criteria for migrainous infarction
•	 ischemic stroke in a migraine sufferer may be cat-
egorized as cerebral infarction of other cause co-
existing with migraine or cerebral infarction of 
other cause presenting with symptoms resembling 
migraine with aura
1.5.5 Migraine-triggered seizure
A seizure triggered by a migraine aura. While 
migraine-like headaches are frequently seen in the 
postictal period, sometimes a seizure occurs during or 
following a migraine attack. 
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A. Migraine fulfilling criteria for 1.2. Migraine with 
aura
B. A seizure fulfilling diagnostic criteria for one type 
of epileptic attack occurs during or within 1 hour 
after a migraine aura
1.6 Probable migraine
1.6.1 probable migraine without aura
A. Attacks fulfilling all but one of criteria A-D for 
1.1. Migraine without aura
B. not attributed to another disorder
1.6.2 probable migraine with aura
A. Attacks fulfilling all but one of criteria A-D for 
1.1. Migraine with aura or any of its subforms
B. not attributed to another disorder
1.6.5 probable chronic migraine
A. headache fulfilling criteria C and D for 1.1. Mi-
graine without aura on >15 days/month for >3 
months
B. not attributed to another disorder, but there is, or 
has been within last 2 months, medication overuse 
fulfilling criterion B for any of the subforms of 8.2. 
Medication-overuse headache
proposed new subclassification
*A 1.1 Migraine without aura:
A1.1.1 pure menstrual migraine without aura
Diagnostic criteria:
Attacks, in a menstruating woman, fulfilling criteria 
for 1.1 Migraine without aura
Attacks occur exclusively on day 1±2 (i.e. days -2 to 
+3) of menstruation in at least two of three menstrual 
cycles and at no other times of the cycle
notes:
The first day of menstruation is day 1 and the pre-
ceding day is day -1; there is no day 0.
for the purposes of this classification, menstrua-
tion is considered to be endometrial bleeding re-
sulting from either normal menstrual cycle or from 
withdrawal of exogenous progestagens, as in case of 
combined oral contraceptives and cyclic hormone re-
placement therapy.
A1.1.2 Menstrually-related migraine without aura
Diagnostic criteria:
Attacks, in a menstruating woman, fulfilling criteria 
for 1.1 Migraine without aura
Attacks occur on day 1±2 (i.e. days -2 to +3) of men-
struation in at least two out of three menstrual cycles 
and additionally at other times of the cycle
notes:
The first day of menstruation is day 1 and the pre-
ceding day is day -1; there is no day 0.
for the purposes of this classification, menstrua-
tion is considered to be endometrial bleeding re-
sulting from either normal menstrual cycle or from 
withdrawal of exogenous progestagens, as in case of 
combined oral contraceptives and cyclic hormone re-
placement therapy.
A1.1.3 non-menstrual migraine without aura
Diagnostic criteria:
Attacks, in a menstruating woman, fulfilling criteria 
for 1.1 Migraine without aura
Attacks have no menstrual relationship
note:
That is, they do not fulfill criterion B for A1.1.1 
pure menstrual migraine without aura or A1.1.2 
Menstrually-related migraine without aura.
Comments:
This subclassification of 1.1 Migraine without aura 
is applicable only to menstruating women.
The importance of distinguishing between A1.1.1 
pure menstrual migraine and A1.1.2 Menstrually-
related migraine is that hormone prophylaxis is more 
likely to be effective for pure menstrual migraine. 
Documented prospectively recorded evidence, kept 
for a minimum of three cycles, is necessary to confirm 
the diagnosis, as many women over-report an asso-
ciation between attacks and menstruation. Menstrual 
attacks are mostly migraine without aura. in a woman 
who has migraine both with and without aura, mi-
graine with aura does not appear to be associated with 
menstruation23.
Migrainous vertigo was not included into the 
ihS criteria for migraine, although epidemiological 
data show a relatively high prevalence among mi-
graineurs24-26.
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Treatment of migraine
Migraine sufferers in need of medical care should 
be encouraged to enter the health care system, con-
sult their physicians, and obtain appropriate treat-
ment. improved migraine diagnosis is required and 
improved strategies for treating migraine are needed 
because many migraine sufferers are dissatisfied with 
current treatment. Most migraine sufferers rely on 
over-the-counter (otC) medications and many do 
not achieve effective relief. About half of all migraine 
sufferers do not consult their physicians for head-
ache27. A community based study in Croatia revealed 
similar results: only 16.8% of patients with migraine 
pay regular visits to physicians, while 36.3% never vis-
ited a physician. The same study revealed that specific 
antimigraine therapy was taken by half of patients 
with migraine: 35.7% of patients used triptans and 
21.7% ergotamines. prophylactic treatment was used 
by 13.9% of migraine patients, 1.2% of tth, and 
6.9% of probable migraine patients28.
General principles of management
1. establish the right diagnosis – an accurate diagno-
sis facilitates successful management of migraine.
2. educate migraine patients about their headache 
type and possibilities of treatment; discuss the pro 
and cons for a particular treatment, how and when 
to use it, and possible adverse events.
3. Discuss the expected benefits and goals of therapy 
and the expected time to achieve them (give real-
istic information).
4. treatment choice depends on the frequency and 
severity of attacks, the presence and degree of tem-
porary disability and associated symptoms such as 
nausea and vomiting; therefore encourage patients 
to take an active part in the management of the 
headache by using diary cards, headache calendars 
– writing down the possible triggers, days of dis-
ability or missed work, school or social activities.
5. educate the patient to identify and avoid the pos-
sible triggers.
6. Develop an appropriate, individualized manage-
ment plan: consider the individual patient response 
and tolerance to specific medications. The program 
should include behavioral and educational issues, 
acute treatment and preventive pharmacotherapy 
in selected patients.
7. Consider comorbidity (coexisting conditions) such 
as heart disease, uncontrolled hypertension, thy-
roid disease, pregnancy, severe liver/kidney dam-
age, as they may limit treatment choices.
each individual headache must be evaluated in 
the context of the patient’s prior migraine attacks. 
The practitioner must always remain alert to the pos-
sibility of secondary causes for headache, particularly 
when there is a previously established history of a pri-
mary headache disorder such as migraine.
Categorize according to peak severity based on 
functional impairment, duration of symptoms, and 
time to peak impairment.
Severity levels:
Mild – the patient is aware of a headache but is able 
to continue daily routine with minimal alteration.
Moderate – the headache is significant enough to 
interfere substantially with daily activities but is not 
completely incapacitating.
Severe – the headache is significant enough to 
limit all activities or greatly alter them.
Status – a severe headache that lasted for more 
than 72 hours.
This categorization influences the choice of treat-
ment method. for example, parenteral administration 
(subcutaneous, nasal) should strongly be considered 
for people whose time to peak disability is <1 hour, 
who awaken with headache, and for those with severe 
nausea and vomiting.
i recommendations for acute treatment of migraine 
attacks
principles and recommendations for treatment of 
acute migraine attacks are as follows5,29-43: 
1. treat attacks rapidly (educate the patient to begin 
treatment as soon as possible); failure to use an ef-
fective treatment promptly may increase and pro-
long pain and disability.
2. use medications and dosages that will have no or 
minimal adverse events (individual approach). The 
administered dose should be in therapeutic range. 
Migraine treatment requires higher doses of anal-
gesics than usually recommended for other head-
aches. 
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3. a) patients with mild to moderate headache – use 
nonsteroidal anti-inflammatory drugs (nSAiDs) 
or combinations such as aspirin plus paracetamol 
plus caffeine and antiemetics; if response to these 
medications is poor, use triptans (or dihydroergot-
amine, Dhe);
b) patients with moderate to severe headache – use 
migraine specific agents (triptans, Dhe); 
c) select a non-oral route of administration for pa-
tients with migraine associated with severe nausea 
or vomiting; nausea is one of the most disabling 
symptoms of a migraine attack and should be treat-
ed appropriately. Therefore antiemetics should not 
be recommended only to patients who are vomit-
ing or are likely to vomit.
4. Minimize the use of back-up and rescue medica-
tions, better use higher initial dose (a rescue medi-
cation is used at home when other treatments fail 
and permits the patient to achieve relief without 
the discomfort and expense of a visit to the physi-
cian’s office or emergency department).
5. educate patients against medication overuse (do 
not induce “rebound headache” or “drug-induced 
headache”); frequent use of acute medications 
such as ergotamines (not Dhe), opiates, triptans, 
simple analgesics and mixed analgesics containing 
butalbital, caffeine or isometheptene) is generally 
thought to cause medication overuse headache.
6. Be cost-effective for overall management.
A wide array of data regarding acute migraine 
treatment are available, but few trials strictly adhere 
to ihS guidelines for patient inclusion criteria.
Acute treatment can be nonspecific (analgesics, 
nSAiDs, opioids, combinations) or specific (triptans, 
ergot alkaloids and derivatives). nonspecific drugs 
control a whole spectrum of pain disorders and in 
some cases the migraine pain, whereas specific drugs 
are effective in migraine but are not effective in non-
headache pain disorders. The choice of treatment 
depends on the severity and frequency of attacks, 
associated symptoms, coexistent disorders, previous 
treatment response, efficacy of the drug, the potential 
for overuse and adverse events. 
triptans or Dhe are first-line drugs for severe at-
tacks and for less severe attacks that do not adequately 
respond to analgesics. triptans appear to have similar 
efficacy profiles, but among newer triptans, almotrip-
tan offers improved tolerability over sumatriptan. Thus 
nSAiDs, particularly effervescent aspirin, should be 
considered the first-line treatment of migraine at-
tacks. Multi-targeted combination therapy with a 
triptan plus a nSAiD such as sumatriptan/naproxen 
sodium is more effective in acute migraine treatment 
than monotherapy with either agent alone. A non-oral 
route of administration combined with an antiemetic 
should be applied in cases of severe nausea and vom-
iting. A recent study regarding prescription patterns 
in acute treatment of migraine showed that nSAiDs 
were used more often than triptans35,36,39,41,42.
nonspecific medications
nSAiDs and non-opioid analgesics
Analgesics, nSAiDs and acetylsalicylic acid 
(ASA) are thought to act via inhibition of prostaglan-
din synthesis and can affect peripheral receptors and 
the release of inflammatory mediators. 
The most consistent evidence of efficacy is avail-
able for ASA, naproxen sodium, ibuprofen (level A) 
and diclofenac potassium (level B); these medications 
have good tolerability, wide dose range and relatively 
few side effects. 
Aspirin 1000 mg is an effective treatment for acute 
migraine headaches, similar to sumatriptan 50 mg or 
100 mg. Addition of metoclopramide 10 mg improves 
relief of nausea and vomiting44. ibuprofen is an effec-
tive treatment for acute migraine headaches, provid-
ing pain relief in about half of sufferers, but complete 
relief from pain and associated symptoms for only a 
minority; number needed to treat for all efficacy out-
comes were better with 400 mg than 200 mg in com-
parison with placebo, and soluble formulations pro-
vided more rapid relief45.
nSAiDs and combination analgesics containing 
caffeine, paracetamol, ASA are a reasonable first-line 
treatment for mild to moderate migraine attacks or 
severe attacks that have been responsive in the past 
to similar nSAiDs or non-opiate analgesics (level 
A)29.
The combination of aspirin and metoclopramide is 
almost as effective as sumatriptan46.
paracetamol (acetaminophen) alone is not recom-
mended for migraine, except for pregnant migraine 
sufferer (level B). 
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it should be noted that daily or almost daily intake 
of analgesics, nSAiDs or combination of analgesics 
can induce chronic daily headache3. 
general rule: give the adequate dose as early as 
possible (avoid overuse!).
Contraindications: analgesics and nSAiDs – in 
patients with hemorrhagic diathesis or hemocoagula-
tive pathologies, gastric or duodenal ulcer, in patients 
with severe liver or kidney insufficiency; ibuprofen, 
naproxen, piroxicam, diclofenac and ketorolac – in 
congestive heart failure. pregnancy (except paraceta-
mol) – especially in the first trimester. 
Caution is advised in children <16 years; ASA 
should not be continuously used because of the poten-
tial risk of Reye’s syndrome. 
Adverse effects: gastrointestinal symptoms; som-
nolence, asthenia, blood cell disturbances occur less 
frequently; skin rashes, urticarial reactions, asthmatic 
crisis and anaphylactic reactions are rare.
* Most nSAiDs and non-opioid analgesics are available in 
Croatia; only ibuprofen 200 mg and 400 mg can be bought 
as otC drugs and a prescription is needed for the others. 
Some of them are partially covered by the Croatian insti-
tute of health insurance, a prescription is needed.
Barbiturate hypnotics – no randomized, placebo 
controlled trials have established the efficacy of butal-
bital containing agents. Because of the potential of 
drug overuse headache and withdrawal, their use 
should be restricted and carefully monitored47.
opioids are effective in the treatment of migraine 
attacks for patients who do not respond to simple an-
algesics or cannot take ergots or triptans, or as a rescue 
drug. Because of the risk of drug overuse, they should 
be used less than twice a week in patients who have 
severe infrequent headaches29,48. parenteral and oral 
combination use should be considered only when the 
risk of abuse has been addressed and sedation will not 
put the patient at risk. Weak opioids are tramadol, di-
hydrocodeine, codeine; strong opioids are oxycodone, 
sevredol, buprenorphine, fentanyl, hydromorphone. 
* opioids are available in Croatia, a prescription is needed
combination drugs
Combination of mild opioid (such as codeine) 
enhances analgesic effectiveness up to 40%. propy-
phenazone has a high potential of adverse events, 
but is a relatively common drug used in combination 
drugs. Combination drugs should best be avoided be-
cause certain compounds may be hypodosed and other 
should not be taken in excess. however, combinations 
such as simple analgesics and antiemetics have been 
proven to be efficient in acute migraine attack: par-
acetamol 1000 mg alone is an effective treatment for 
acute migraine headaches, and the addition of 10 mg 
metoclopramide gives short-term efficacy equivalent 
to oral sumatriptan 100 mg49. 
Combination drugs common on the market:
ASA 200 mg + paracetamol 200 mg + caffeine 60 mg 
paracetamol 210 mg + propyphenazone 250 mg + caf-
feine 50 mg + codeine 10 mg  
paracetamol 200 + propyphenazone 200 mg + caffeine 
50 mg  
paracetamol 500 mg + caffeine 65 mg 
*all combinations are available in Croatia as otC
other medications
Corticosteroids (dexamethasone or hydrocorti-
sone) are the treatment choice for rescue therapy for 
patients with status migrainosus. Dexamethasone is 
efficacious in preventing headache recurrence and safe 
when added to standard treatment for the manage-
ment of acute migraine headache in emergency de-
partment. When added to standard abortive therapy 
for migraine headache, single dose parenteral dexam-
ethasone is associated with a 26% relative reduction in 
headache recurrence within 72 hours50,51.
Antiemetics
Relatively few studies have investigated their ef-
fectiveness in migraine attacks; in the majority of 
cases, such studies concern combination of analgesics 
or nSAiDs with antiemetics. These associations have 
been proposed to improve the absorption of symp-
tomatic drugs and to act as adjuvant in reducing nau-
sea and vomiting (level C).
Metoclopramide im./iv. is an adjunct to control 
nausea (level C) and may be considered as iv. mono-
therapy for migraine pain relief (level B). Metoclo-
pramide (10 mg) is given either by direct iv. injection 
over 2 to 3 minutes, or in 50 ml of normal saline and 
infused intravenously over 15 minutes. each dose of 
metoclopramide should be administered 15 minutes 
prior to each Dhe injection41. 
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Thiethylperazine and prochlorperazine are ad-
juncts in the treatment of acute migraine with nausea 
and vomiting29,35,37. Chlorpromazine iv. may be thera-
peutic choice for migraine in the appropriate setting 
(level B). 
Current evidence does not support the use of gran-
isetron or zatosetron (5-ht3 antagonists) for symp-
tomatic treatment of migraine attacks as monotherapy 
(level B); such drugs could be considered as adjuvants 
in relieving nausea and vomiting (level C). 
Contraindications: metoclopramide is contraindi-
cated in patients with pheochromocytoma, epilepsy, 
in patients in which it can potentially induce extrapy-
ramidal reactions.
Domperidone is not recommended in patients 
with prolactinoma.
All medications from this group should be used in 
pregnancy only in cases of extreme necessity. 
Adverse effects: metoclopramide, thiethylperazine 
– acute extrapyramidal side effects such as dystonia, 
akathisia, and oculogyric crisis may occur. prochlo-
rperazine, chlorpromazine – drowsiness, sedation, 
postural hypotension.
* Metoclopramide is available as tablets and thiethylpera-
zine as suppository, and are fully covered by the Croatian 
institute of health insurance, a prescription is needed. 
specific medications
triptans (5ht1 agonists, serotonin 1B/1D recep-
tor agonists). 
triptans are effective and relatively safe for the 
acute treatment of migraine and are an appropriate 
initial treatment choice in patients with moderate to 
severe migraine who have no contraindications for its 
use and when nonspecific medication has failed to be 
efficient in the past. A number of controlled studies 
have demonstrated the efficacy of triptans not only on 
headache but also on accompanying symptoms (pho-
tophobia, phonophobia, nausea and vomiting) and on 
functional disability5,54-89.
triptans may be used during the established head-
ache phase of an attack and are the preferred treat-
ment in those who fail to respond to conventional 
analgesics. triptans are effective in the range of mild, 
moderate and severe migraine attacks. triptans should 
be used as soon as possible after headache onset. to 
date, no evidence supports their use during the aura 
phase of a migraine attack. Sumatriptan was the first 
5ht1 agonist to be introduced for treating migraine; 
zolmitriptan, naratriptan, rizatriptan, almotriptan, 
eletriptan and frovatriptan have been introduced 
more recently. An economic analysis of a prospective 
observational 6-month outcomes study of patients 
with migraine showed that initiation of sumatriptan 
in patients previously receiving non-triptan therapy 
was cost-effective and had an economic benefit for pa-
tients, employers and society by reducing patient dis-
ability and thus improving their ability to function at 
work and non-work activities75.
Contraindications: all triptans have the same contrain-
dications and safety concerns. 5ht1 agonists should 
not be used for prophylaxis. They are contraindicated 
in ischemic heart disease, previous myocardial in-
farction, coronary vasospasm (including prinzmetal’s 
angina), uncontrolled hypertension, previous cerebro-
vascular incident or transient ischemic attack, basilar 
or hemiplegic migraine, peripheral vascular disease, 
Wolf-parkinson-White syndrome, arrhythmias as-
sociated with accessory cardiac conduction pathways, 
pregnancy, breast feeding. 
5ht1 agonists should not be taken with ergot-
amins concurrently, or within 6 hours. 
Sumatriptan, zolmitriptan and rizatriptan should 
not be taken with MAo inhibitors, selective serotonin 
reuptake inhibitors (SSRis) and lithium. Rizatriptan 
and zolmitriptan are contraindicated in patients with 
liver dysfunction. 
Cautions: 5ht1 agonists should be used with cau-
tion in conditions which predispose to coronary artery 
disease (pre-existing cardiac disease), hepatic and liver 
impairment, pregnancy and breast feeding. triptans 
can cause drowsiness. triptans are not recommended 
for use in children. 
Caution should be applied in patients over 65 years. 
Sumatriptan and naratriptan contain the sulfonamide 
component, which can cause an allergic reaction. 
Adverse effects: include sensations of tingling, 
heat, heaviness, pressure or tightness of any body part 
(including throat and chest – should be discontinued 
if intense, may be due to coronary vasoconstriction or 
to anaphylaxis; flushing, dizziness, feeling of weak-
ness, fatigue, nausea, vomiting, drowsiness, transient 
increase in blood pressure, hypotension, bradycardia 
or tachycardia, altered liver function tests, erythema 
at injection site, seizures.
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in general practice, triptan treatment in migraine 
does not increase the risk of stroke, myocardial infarc-
tion, cardiovascular death or mortality71. The safety of 
triptans was evaluated in a study measuring coronary 
artery diameter after intravenous eletriptan adminis-
tration; the study demonstrated that in patients with 
normal coronary arteries, eletriptan administered at 
plasma concentrations in excess of 3 times resulted 
in only mild and clinically insignificant degree of 
coronary vasoconstriction72. however, so far in the 
literature, sumatriptan, zolmitriptan, naratriptan 
and frovatriptan have been described to cause acute 
coronary syndromes. Therefore, triptans should not 
be prescribed in patients with pre-existing coronary 
heart disease. Severe or persistent thoracic pain after 
taking triptans should therefore be investigated ac-
cordingly90-92. 
Seven triptans are available on the market (europe, 
uSA):
– Sumatriptan 50 mg, 100 mg po., maximum daily 
dose 300 mg
– Sumatriptan 10 mg, 20 mg nasal spray, 1 single 
dose spray; maximum daily dose 40 mg
 Sumatriptan 6 mg sc., maximum daily dose 12 mg
 Sumatriptan 25 mg supp, maximum daily dose 50 mg
– Zolmitriptan 2.5 mg, 5 mg po., maximum daily 
dose 5 mg
– Zolmitriptan 5 mg nasal spray
– naratriptan 1 mg, 2.5 mg po., maximum daily 
dose 5 mg
– Rizatriptan 5 mg, 10 mg po., maximum daily dose 
30 mg
– Rizatriptan rapid disk (RpD) 10 mg, maximum 
daily dose 30 mg
– eletriptan 20mg, 40 mg, 80 mg po., maximum 
daily dose 80 mg
– Almotriptan 6.25 mg, 12,5 mg, 25 mg po., maxi-
mum daily dose 25 mg
– frovatriptan 2.5 mg po.
* Sumatriptan 50 mg po. (tablet), sumatriptan 20 mg nasal 
spray, zolmitriptan 2.5 mg rapid melting disk and rizatrip-
tan 10 mg rapid melting disk are available in Croatia; su-
matriptan 50 mg po. is fully covered by the Croatian insti-
tute of health insurance and the rest are partially covered, 
a prescription is needed.
Despite the similarities of the available triptans, 
pharmacological heterogeneity offers slightly different 
efficacy profiles, pharmacokinetics, pain response, re-
currence and adverse events.
When deciding which triptan to recommend, mi-
graine severity, rapidity of onset and duration are im-
portant factors. An individual response to a triptan 
cannot be predicted, if the first triptan is not efficient 
another triptan should be recommended; physicians 
thus need more than one triptan to treat migraine pa-
tients optimally. patients who do not have vomiting 
may be given oral triptans. patients with nausea and 
vomiting or rapid onset of headache may be given in-
tranasal or subcutaneous formulations29,54. Controlled 
clinical studies reveal that most of oral triptans have 
broadly similar efficacy profiles. Switching triptans 
can therefore only be recommended if the patient 
experiences problems such as the lack of efficacy or 
intolerable side effects following repeated use of the 
initial triptan93. The response to triptans is often idio-
syncratic; one triptan might be more suitable for one 
patient and other triptans for other patients. in an in-
dividual patient, the triptan of choice is the one that 
relieves the pain and associated symptoms quickly 
with minimum adverse events and without recurrence 
of symptoms. 
All triptans are superior to placebo in clinical tri-
als, and some, such as rizatriptan 10 mg, eletriptan 40 
mg, almotriptan 12.5 mg, and zolmitriptan 2.5 and 5 
mg are very similar to each other and to the prototype 
triptan, sumatriptan 100 mg. These five are known 
as the fast-acting triptans. increased dosing can offer 
increased efficacy but may confer a higher risk of ad-
verse events, which are usually mild to moderate and 
transient in nature. 
naratriptan, rizatriptan and zolmitriptan are full 
agonists, while eletriptan is a partial agonist. Al-
motriptan, eletriptan, rizatriptan, sumatriptan and 
zolmitriptan have the highest 2-hour effectiveness, 
provide headache relief within 30-60 minutes and 
have the least recurrences. A meta-analysis suggests 
that almotriptan 12.5 mg, eletriptan 80 mg and riza-
triptan 10 mg offer the highest likelihood of success. 
The lower doses of these agents (rizatriptan 5 mg and 
eletriptan 40 mg) may be good starting doses.
Sumatriptan 100 mg and 50 mg (oral) provide 
good efficacy and tolerability. The 50 mg dose was 
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comparable with 100 mg and superior to 25 mg in 
4-hour headache relief. Recurrences respond well to a 
second dose of sumatriptan. Subcutaneous sumatrip-
tan (6 mg) is the most effective acute treatment for 
migraine attacks, reaching peak plasma concentra-
tions within 12 min but is also associated with more 
intense adverse events and the need of self-injection. 
Several placebo controlled trials support the efficacy 
of sumatriptan nasal spray for headache relief at 1 and 
2 hours; a dose-response relationship was demonstrat-
ed, with superiority to placebo at the 10, 20 and 40 
mg doses. Sumatriptan is metabolized mainly by the 
monoamine oxidase (MAo-A) and is contraindicated 
in patients using MAo inhibitors. Substantial drug 
interactions with other traditional migraine-preven-
tive medications, including beta blockers, calcium 
channel antagonists, SSRis and tricyclic antidepres-
sants were not found. 
Zolmitriptan has oral bioavailability of 40%, half 
life about 2.5 hours and is metabolized by the cyto-
chrome p450 system. no significant difference was 
found between 2.5 mg and 5 mg doses. The recom-
mended starting dose of 2.5 mg provides the best 
balance of benefit and side effects, although some pa-
tients may benefit from the 5 mg dose. Both 2.5 mg 
and 5 mg doses of zolmitriptan were comparable to 
sumatriptan 50 mg and 100 mg for headache relief, 
consistency of response and 24-hour headache relief 
rates. nasal spray (available in some countries) is de-
tectable in blood within 5 minutes. 
naratriptan has a longer half life (6 hours) and 
higher oral bioavailability (70%). Relief rates have 
been found to be lower than with other oral triptans. 
Compared with sumatriptan, one-third fewer patients 
experienced recurrence headache. naratriptan 2.5 mg 
offers very good tolerability coupled to a slower onset 
of improvement, thus naratriptan can be offered in pa-
tients with mild to moderate migraine. 
Rizatriptan has rapid oral absorption and high 
oral bioavailability (45%) at 10 mg dose. There is no 
significant difference at 2 hours between sumatriptan 
and lower doses of rizatriptan. Rizatriptan is metabo-
lized mainly by MAo-A, plasma concentrations are 
increased in patients taking propranolol (in which 
cases the recommended dose should not exceed 5 mg); 
interaction with other beta-blockers has not been ob-
served. 
Almotriptan 6.25 mg and 12.5 mg is clinically sig-
nificant in relieving migraine symptoms. Almotriptan 
does not interact with propranolol, SSRis or MAo. 
frovatriptan was effective and well tolerated across 
a wide range of doses (2.5, 5, 10, 20 or 40 mg) and 
low recurrence rates were observed. frovatriptan is 
metabolized by the cytochrome p450 system. 
eletriptan is rapidly absorbed, with high bioavail-
ability (50%) and a long half-life (5 hours); it interacts 
with drugs that are metabolized by the cytochrome 
p450 system. headache response rates were higher in 
eletriptan (40 to 80 mg) than in sumatriptan (50 to 
100 mg) group at 1 and 2 hours. Adverse events are 
more common with eletriptan 80 mg than with other 
triptans. 
The triptans which had a longer half life and 
higher 5-ht1B receptor potency – frovatriptan 2.5 
mg, naratriptan 2.5 mg and eletriptan 80 mg, had the 
lowest rates of headache recurrence.
tables 1 and 2 show pharmacokinetic variables for 
5-ht1B/1D agonists56. 
t max (h) t ½ Bioavailability (%)
Sumatriptan 2.5 2.5 15
Zolmitriptan 2 2.5-3 40-48
Rizatriptan 1-1.5 2-3 45
naratriptan 2-4 5.6-6.3 74 (women), 63 (men)
eletriptan 1-2 3.6-5.5 50
frovatriptan 2-4 25 24-30
Almotriptan 1.4-3.8 3.2-3.7 70
Table 1. Pharmacokinetic variables for oral 5-HT1B/1D agonists
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ergot alkaloids and derivatives
ergot alkaloids were the first specific antimi-
graine therapy available. however, with the advent 
of  triptans, their use in the treatment of migraine 
has declined and their role has become less clear. in 
randomized clinical trials, oral ergotamine was found 
to be superior to placebo, but inferior to 100 mg of 
oral sumatriptan. in contrast, rectal ergotamine was 
found to have higher efficacy (73% headache relief) 
than rectal sumatriptan (63% headache relief). intra-
nasal Dhe was found to be superior to placebo, but 
less effective than subcutaneous and intranasal su-
matriptan94. ergotamine is still widely used in some 
countries for the treatment of severe migraine attacks. 
it is generally regarded as a safe and useful drug if 
prescribed for infrequent use, in a correct dose, and in 
the absence of contraindications.
ergotamine tartarate, in association with caffeine 
or not (caffeine doubles the rate of absorption of er-
gotamine and increases the peak in blood concentra-
tion), is significantly effective in reducing head pain 
in migraine attack; a low incidence of headache recur-
rence has been observed95. The value of ergotamine in 
the treatment of migraine is limited by difficulties in 
absorption and by its side effects. ergots have much 
greater receptor affinity at 5-ht1a, 5-ht2, adrener-
gic and dopaminergic receptors than triptans, leading 
to more adverse events. ergot derivatives may worsen 
nausea and vomiting, thus co-administration of an 
antiemetic is indicated. ergot derivatives are vasos-
pastic and may cause a rise in blood pressure level. 
Co-administration with triptans is contraindicated 
within 6 hours. 
Ddihydroergotamine (Dhe) administered by par-
enteral route was the treatment of choice for migraine 
attack until the introduction of triptans. Dhe is ef-
fective in alleviating head pain during migraine attack 
and is better tolerated than ergotamine tartarate96. 
Dhe sc. And nasal spray formulation is less effec-
tive than subcutaneously administered sumatriptan 
in relieving head pain and accompanying symptoms, 
but is associated with a small percentage of headache 
recurrence97. Dhe nasal spray is safe and effective for 
the treatment of acute migraine attacks and should be 
considered for use in patients with moderate to severe 
migraine with or without nausea and vomiting, or in 
migraine of any severity when nonspecific medication 
(or triptans) has failed to provide adequate relief in 
the past.
The recommended doses of ergotamine prepara-
tions should not be exceeded and treatment should 
not be repeated at interval of less than 4 days. triptans 
and ergot derivatives are associated with an increased 
risk of drug dependence; patients who regularly use 
ergot derivatives for more than 2-3 days/week can de-
velop rebound headache98,99. The abuse of ergot deriv-
atives may induce an increase in attack frequency and 
Table 2. Pharmacokinetic variables for 5-HT1B/1D agonists 
 Dose pain response pain response pain free Recurrence 
  mg 2 h (%) 4 h (%) 2 h (%)
Sumatriptan po. 50 63 77 28 28
Sumatriptan po. 100 59 – 29 30
Sumatriptan nasal spray 20 61 – 27-37 –
Sumatriptan sc. 6 69 – 49 –
Zolmitriptan po. 2.5 64 73 25 30
Zolmitriptan po. 5 66 73-77 34 34
Rizatriptan po. 5 62 – 30 39
Rizatriptan po. 10 69 84 40 37
naratriptan po. 2.5 49 60-68 22 21
eletriptan po. 40 60 – 27 21
eletriptan po. 80 66 88 33 20
Almotriptan po. 12.5 61 – 36 26
frovatriptan po. 2.5 42 64 – –
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develop into chronic daily headache. to avoid habitu-
ation, the frequency of administration of ergotamine 
should be limited to no more than twice a month. 
Their use is not recommended in the treatment of at-
tacks of medium or high frequency, for the potential 
risk of abuse. ergotamine should best be avoided if 
possible (consider other therapies such as triptans). 
oral triptans are superior to oral ergotamine most 
likely because the bioavailability of oral ergotamine is 
extremely low (<1%).
Contraindications: peripheral vascular disease, 
cerebrovascular disease, coronary heart disease, mitral 
stenosis, obliterative vascular disease and Raynaud’s 
syndrome, hepatic and renal impairment, sepsis, se-
vere or inadequately controlled hypertension, hyper-
thyroidism, pregnancy and breast feeding, porphyria, 
liver and renal failure. 
Dhe is relatively contraindicated if blood pres-
sure is sustained >165/95100.
Cautions: risk of peripheral vasospasm (in patients 
who are concomitantly using beta blockers), elderly, 
dependence, should not be used for migraine prophy-
laxis. 
ergot derivatives should not be administered 
within 6 hours after the administration of triptans. 
Macrolide antibiotics increase plasma levels of er-
gotamine derivatives. 
Adverse events: nausea, vomiting, abdominal pain, 
diarrhea, muscle cramps, occasionally increased head-
ache, distal paresthesias, precordial pain, myocardial 
ischemia – rarely infarction; chronic use or repeated 
high dose may cause ergotism with gangrene and con-
fusion, ischemic neuropathies, pericardial, pleural and 
peritoneal fibrosis101.
* ergotamine and dhe are not registered in croatia. 
evidence summary for treatment of acute attacks 
of migraine are listed in table 3.
Clinical stratification of acute migraine treatment 
is listed in table 4. 
migraine status 
The principles of treatment for status migrainosus 
include the following:
1. Consider brain imaging
2. fluid replacement and correction of metabolic pa-
rameters (if indicated) for 24-48 hours
Table 3. Evidence summary for treatment of acute mi-
graine attacks
Drug level Clinical 
 of evidence effectiveness
triptans
Sumatriptan sc. A +++
Sumatriptan nasal spray A +++
Sumatriptan oral A +++
Zomitriptan oral A +++
Rizatriptan oral A +++
naratriptan oral A ++
eletriptan oral A +++
Almotriptan oral A +++
ergot alkaloids and derivatives
ergotamine oral, B +
suppository, im., sc. 
ergotamine + caffeine B +
Dhe iv., im., sc. B +++
Dhe nasal spray A ++
Antiemetics
Chlorpromazine C/B ++
Metoclopramide im. B +
prochlorperazine im. B +/++
nSAiDs and non-opiate analgesics (oral)
paracetamol B +
Aspirin A ++
Diclofenac B ++
ibuprofen A ++
naproxen B ++
naproxen sodium A ++
indomethacin oral, supp C +
Ketoprofen B ++
(parenteral)
Ketorolac im. B ++
Combination of:
paracetamol, aspirin, caffeine A ++
Barbiturate hypnotics
Butalbital, ASA, 
caffeine C +++
opiates
opiates oral A ++
opiates parenteral B ++
other
Corticosteroids C ++
lidocaine intranasal B ?
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3. Drug detoxification
4. parenteral pharmacotherapy 
a) analgesics, nSAiD and antiemetics up to max-
imum daily dose
b) sedatives (diazepam) 5-10 mg im.(or iv.)
c) consider oral, im. or iv. neuroleptics in an inpa-
tient setting (the patient should be observed in 
a medical setting and should be monitored for 
hypotension, sedation and dystonic reactions)
d) parenteral corticosteroids alone or in combina-
tion with other symptomatic medications may 
Table 4. Clinical stratification of acute migraine treatment
Drug Recommended dosage Maximum daily  
  dose
1. Analgesics, nSAiD
1) paracetamol 500-1000 mg po. 2000 mg
2) Acetylsalicylic acid 500-1000 mg po. 2000 mg
3) ibuprofen 400-800 mg po. 1800 mg
4) Diclofenac 50-100 mg po., im., supp 200 mg
5) Ketoprofen 50-100 mg po., im., supp 200 mg
6) naproxen 500-1000 mg po., supp 1500 mg
7) piroxicam 20 mg po., im., supp 40 mg
combination: paracetamol, aspirin, caffeine with or without antiemetic
Antiemetics 
1) Metoclopramide 10 mg po., iv., im. 30 mg
2) Thiethylperazine 6.5 mg po. 13 mg
3) prochlorperazine 10 mg supp 20 mg
4) Chlorpromazine 0.1 mg/kg im. 1 mg/kg
2. Analgesics or nSAiD failed, try
1) Sumatriptan 50-100 mg po. 300 mg
2) Zolmitriptan 2.5-5.0 mg po. 5 mg
3) Rizatriptan 5-10 mg po., Mlt wafer* 30 mg
4) naratriptan 2.5 mg po. 5 mg
5) eletriptan 80 mg po. 80 mg
6) Almotriptan 12.5-25 mg po. 25 mg
3. early nausea, vomiting or problem taking tablets 
1) Sumatriptan 20 mg nasal spray 40 mg
2) Sumatriptan 6 mg sc. if available 12 mg
3) Rizatriptan 10 mg Mlt wafer* 30 mg
4) Dhe 0.5-2 mg nS 2 mg
4. headache recurrence or long lasting headache
1) naratriptan 2.5 mg po. 5 mg
2) other triptans
3) Dhe 0.5-2 mg nasal spray 2 mg
5. very rapidly developing symptoms
1) Sumatriptan 6 mg sc.
2) Sumatriptan 20 mg nasal spray
6. tolerating triptans poorly
Dhe 0.5-2 mg nasal spray 2 mg
*Mlt = melting wafer
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be used to treat severe, resistant headaches: 
prednisone up to 100 mg/day rapidly tapering 
short course will assist in terminating an oth-
erwise refractory migraine
1. Concurrent implementation of migraine prophy-
laxis (if indicated)
2. Consider admission in cases of
a) drug abuse
b) exacerbation of comorbid diseases
c) therapy that requires inpatient monitoring
* patients to whom iv. sedatives and neuroleptics have been 
administered should not drive for at least 24 hours. 
ii recommendations for preventive therapy of 
migraine attacks
Consistent evidence exists, from several random-
ized, controlled studies, for the efficacy of various 
medications in migraine prophylaxis. The various 
effective preventive agents used in migraine prophy-
laxis, such as topiramate, valproate, β-blockers, and 
tricyclic antidepressants, appear to have a common 
effect of suppressing cortical excitability102. Consider-
ing resource utilization, various studies suggest that 
migraine prophylaxis with antiepileptics, antidepres-
sants, beta-blockers or calcium channel antagonists 
markedly reduces triptan use and visits to physician 
offices and emergency departments. prophylactic 
therapy appears to be an effective option, particularly 
with respect to decreasing resource use and improving 
productivity103,104.
The principles and recommendations for pre-
ventive treatment of migraine attacks are as fol-
lows5,88,101,105-119. 
prior to instituting prophylactic therapy for mi-
graine, it is imperative that realistic goals and expec-
tations be established. patients should have clear un-
derstanding that the goals of preventive therapy are 
to:
1. reduce attack frequency, severity and duration; it 
is generally accepted that a good response to pro-
phylactic therapy is at least a 50% reduction in the 
frequency or severity of migraine attacks
2. improve responsiveness to treatment of acute at-
tacks
3. improve function and quality of life
Who should be offered prophylactic treatment and 
when:
•	 frequent headaches, >2-3 migraine attacks per 
month
•	 attacks lasting >48 hours
•	 attacks described by patients as unbearable, or 
that significantly interfere with daily activities 
despite acute treatment
•	 contraindication to or failure or overuse of 
acute therapies
•	 adverse events with acute therapies
•	 patient preference
•	 presence of uncommon migraine conditions in-
cluding hemiplegic migraine, basilar migraine, 
migraine with prolonged aura or migrainous 
infarction (to prevent neurologic damage)
principles of preventive treatment:
1. Medication use:
•	 initiate therapy with medications that have the 
highest level of evidence-based efficacy
•	 initiate therapy with the lowest effective dose 
of the drug; increase it slowly until clinical 
benefits are achieved until limited by adverse 
events
•	 give each drug an adequate trial; it may take 2 
to 3 months to achieve clinical benefit
•	 avoid interfering medications (overuse of acute 
medications)
•	 use of a long-acting formulation may improve 
compliance
2. evaluation:
•	 monitor the patient’s headache frequency 
through a headache diary
•	 re-evaluate therapy; if after 6-12 months head-
aches are well controlled, consider tapering or 
discontinuing treatment
3. take coexisting conditions into account. Several 
conditions are more common in persons with mi-
graine: stroke in certain subgroups of patients, 
myocardial infarction, Raynaud’s phenomenon, 
epilepsy, affective and anxiety disorders. These 
conditions present both treatment opportunities 
and limitations: 
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•	 select a drug that will treat the coexistent con-
dition and migraine, if possible
•	 establish that the treatment being used for mi-
graine is not contraindicated for the coexisting 
disease
•	 establish that the treatment being used for co-
existing condition does not exacerbate migraine 
attacks
•	 beware of all drug interactions
4. Special attention is warranted in pregnant women 
or women who wish to become pregnant in near 
future. preventive medications may have terato-
genic effects. if treatment is absolutely necessary, 
select a treatment with the lowest risk of adverse 
effects to the fetus
5. nonpharmacological treatment 
over the past two decades, several behavioral 
treatments for migraine prevention have been used 
widely as independent therapies or combined with 
pharmacological therapy. These therapies may be par-
ticularly well suited as treatment options for headache 
sufferers who have one or more of the following char-
acteristics:
•	 patient preference for nonpharmacological 
treatment
•	 poor tolerance to specific pharmacological 
treatments
•	 medical contraindications for specific pharma-
cological treatments
•	 insufficient or no response to pharmacological 
treatment
•	 pregnancy, planned pregnancy, or nursing
•	 history of long-term, frequent, or excessive use 
of analgesics or acute medications that can ag-
gravate headache problems
•	 significant stress 
if the prophylactic therapy is successful, continue 
treatment for 6-12 months, then reassess the patient. 
if success is achieved with a particular prophylac-
tic medication after approximately 6 to 12 months, 
gradual tapering is recommended and the patient 
should be observed for increased headache frequency 
or intensity.
try different first line medications or different 
drugs of the same class. 
Table 5. Evidence for prophylactic drug treatment in 
migraine
Drug level Clinical
 of evidence effectiveness
Beta blockers
Atenolol A +++
propranolol A +++
nadolol B ++
Metoprolol B ++
Ca channel blockers
flunarizine A +++
nimodipine B +
verapamil B +
Antidepressants 
Amitriptyline A +++
nortriptyline C +
Doxepine C +
imipramine C +
SSRis
fluoxetine B +
paroxetine B +
Antiepileptics
Sodium valproate A ++
gabapentin A ++
topiramate B ?
lamotrigine B ?
Serotonin antagonists
pizotifen A +++
lisuride A +
Dihydroergotamine A +++
nSAiDs B ?
other
estradiol B ++
vitamin B2 B ++
Magnesium B +
tanacetum B ?
parthenium
Botulinum toxin B ++
Monotherapy is generally recommended. A single 
agent is employed at a gradually increasing dosage 
(within prescribed limits) until dose-limiting side ef-
fects or therapeutic efficacy occurs. it is important to 
remember that therapeutic failure with one medica-
tion does not preclude the potential for benefit with 
another medication from the same class.
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Try combination of beta-blockers and tricyclics 
it is an established observation that certain com-
binations, particularly a beta-blocker and a tricyclic 
antidepressant, may be more efficacious and produce 
fewer side effects in combination (at lower doses) than 
either medication in isolation (at higher single doses).
prophylactic drug treatment in migraine accord-
ing to the levels of evidence and clinical effectiveness 
are listed in table 5101. 
The choice of prophylactic medication should be in-
dividualized according to the potential efficacy and side 
effect profile of the medication, as well as the presence 
of any associated comorbid medical conditions or med-
ication interactions. on the other hand, some comorbid 
illnesses affect prophylactic choices. prophylactic treat-
ment should be started at low doses, possibly as mono-
therapy; doses can be slowly increased until therapeutic 
goals are achieved and the side effects are minimal. 
patients should also understand that there is usually a 
latency of at least 3 to 6 weeks between the initiation of 
medication and recognizable efficacy. often, an 8- to 
12-week trial is necessary, allowing an adequate period 
for drug titration to a dosage likely to attain efficacy. 
long-acting formulations can improve compliance. it 
is also not uncommon for initial side effects to subside 
after continued therapy, and patients should be aware 
of this so as to avoid premature discontinuation of a 
potentially effective medication. 
prophylactic treatment during pregnancy should 
best be avoided, if necessary, limited to special situ-
ations; in these cases, drugs with lowest risk to the 
fetus should be selected. 
patients should carefully fill out headache diaries 
where the frequency, duration of attack, severity of 
pain, functional impairment, disability are recorded 
as well as taken drugs and possible adverse events. 
Pharmacological treatment
Beta blockers
prophylaxis of migraine headache by beta blockers 
was incidentally detected in patients treated for hyper-
tension who also had migraine headaches. The mech-
anism is not clear, although it is probably by acting 
on the central monoaminergic system and serotonin 
receptors. Beta blockers considered to be effective in 
migraine prophylaxis are propranolol, atenolol, meto-
prolol and timolol30,101,105,120. A meta-analysis which 
included 74 controlled studies has shown that propra-
nolol was consistently effective for migraine preven-
tion in a daily dose of 120-240 mg. no absolute cor-
relation has been found between propranolol dose and 
its clinical efficacy. on average, propranolol yielded a 
44% reduction in migraine activity compared with a 
14% reduction with placebo105,121,122. 
Therapy should be started with low doses and then 
slowly increased if necessary. When migraine attacks 
are controlled, doses can be reduced slowly. Abrupt 
cessation of therapy with beta blockers might induce 
rebound effects by increasing migraine attacks and in-
ducing adrenergic side effects and hypertension. 
propranolol. The therapeutically effective dose of 
propranolol ranges from 40 to 400 mg a day; therapy 
should be started at a dose of 40 mg a day in 2 doses 
and slowly increased to tolerance. The short-acting 
form can be given four times a day, although we rec-
ommend twice a day, and the long-acting form once 
or twice a week. 
timolol has a short half-life, doses range from 20 
mg to 60 mg a day in divided doses.
Atenolol has fewer side effects than propranolol, 
the dose ranges from 50 mg to 200 mg a day once 
daily.
Metoprolol has a short half-life, doses range from 
100 mg to 200 mg a day in divided doses, long-acting 
preparation may be given once a day.
no migraine prophylaxis activity has been shown 
for acebutol, alprenolol, oxprenolol and pindolol.
Contraindications: congestive heart failure, asth-
ma, insulin dependent diabetes, Raynaud’s disease
Cautions: abrupt stopping of therapy with beta 
blockers can cause increased headache, withdrawal 
symptoms of tachycardia and tremulousness.
Adverse events: drowsiness, dizziness, nausea, 
fatigue, lethargy, sleep disorder, nightmares, depres-
sion, memory disturbance, hallucinations, orthostatic 
hypotension, significant bradycardia, impotence. 
* most beta-blockers are available in Croatia, covered by the 
Croatian institute of health insurance (100%), a prescrip-
tion is needed. 
Antidepressants
only tricyclic antidepressants have proven efficacy 
in migraine. The mechanism by which antidepressants 
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exert headache prophylaxis is uncertain, but does not 
result from treating masked depression. Amitriptyline 
modulates monoaminergic pathways by inhibiting the 
reuptake of both adrenaline and serotonin. tricyclic 
antidepressants are effective in preventing migraine 
and tension-type headaches and are more effective than 
SSRis, although with greater adverse effects. The effec-
tiveness of tricyclics seems to increase over time123. 
Amitriptyline is the only antidepressant with fairly 
consistent support for efficacy in migraine prevention; 
placebo controlled trials found amitriptyline signifi-
cantly better than placebo in reducing headache index 
or frequency124.
The effective dose varies; treatment should be 
started with an initial dose of 10 mg in the evening, to 
be increased by 10 mg per week to up to a maximum 
of 50 mg per day101,124. high doses could be necessary 
in the presence of depression. 
one trial comparing propranolol and amitriptyline 
has suggested that propranolol is more efficacious in 
patients with migraine alone and amitriptyline is su-
perior for patients with the phenotypes of migraine 
and tension type headache125.
Contraindications: severe cardiac, liver, renal, pro-
static and thyroid diseases, glaucoma, hypotension, 
convulsive disorders, concomitant use of MAo in-
hibitors. 
Caution in elderly patients because of anticholin-
ergic effects. Antidepressant treatment may also re-
duce seizure threshold. 
Adverse effects: orthostatic hypotension, dry 
mouth, metallic taste, epigastric distress, constipa-
tion, dizziness, mental confusion, tachycardia, blurred 
vision, urinary retention. 
*Amitriptyline is available in Croatia, covered by the Croa-
tian institute of health insurance (100%), a prescription is 
needed.
SSRis (fluoxetine, fluvoxamine, paroxetine, sertra-
line, citalopram) and SSRis/selective noradrenaline-
reuptake inhibitors (SnRis) (venlafaxine, duloxetine)
Recent studies have shown that venlafaxine and 
escitalopram are both effective in the prophylaxis of 
migraine headache without depression and anxiety; 
this effect was independent of mood disorder. escit-
alopram should be the first choice because of its fewer 
side effects, but venlafaxine may be used if escitalo-
pram is found to be insufficient126,127. 
Most studies, however, show that over 2 months of 
treatment, SSRis are no more efficacious than placebo 
in patients with migraine128. At the moment, there 
is no definitive evidence supporting the use of these 
drugs in preventing migraine attacks129,130. 
With only Class iv evidence available in the lit-
erature, inadequate data are available to determine the 
risk of serotonin syndrome with the addition of a trip-
tan to SSRis/SnRis or with triptan monotherapy. The 
currently available evidence does not support limiting 
the use of triptans with SSRis or SnRis, or the use 
of triptan monotherapy, due to concerns for serotonin 
syndrome (level u). however, given the seriousness 
of serotonin syndrome, caution is certainly warranted 
and clinicians should be vigilant to serotonin toxicity 
symptoms and signs to insure prompt treatment131.
* SSRis and SnRis are available in Croatia, covered by the 
Croatian institute of health insurance (100%), a prescrip-
tion is needed.
calcium channel antagonists
Calcium channel blockers act by modulating neu-
rotransmission, inducing vasodilatation and exerting 
a cytoprotective effect by preventing the influx of cal-
cium ions into the cells and reducing cell damage due 
to hypoxia. 
nifedipine and nimodipine have been shown to 
be ineffective, while verapamil has shown to be mar-
ginally effective; there is no randomized controlled 
trial evidence to support the use of verapamil in mi-
graine105,107. Cyclandelate has comparable efficacy 
with that of beta blockers and only a few side ef-
fects132.
flunarizine. Among all available drugs of this 
class (flunarizine, nimodipine, nifedipine, verapamil, 
cyclandelate, nicardipine), flunarizine was the most 
effective drug, showing no significant differences 
when compared with beta blockers105,133-135. The 
recommended dose of flunarizine is 5-10 mg a day. 
flunarizine is not available in Croatia.
Contraindications: pregnancy, hypotension, heart 
failure, atrioventricular block, parkinson’s disease, 
depression. 
Adverse effects: weight gain, somnolence, dry 
mouth, dizziness, hypotension, occasional extrapyra-
midal reactions, exacerbation of depression, abdomi-
nal pain
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* verapamil, nifedipine and nimodipine are available in 
Croatia, covered by the Croatian institute of health insur-
ance (100%), a prescription is needed.
serotonin antagonists
pizotifen and methysergide are 5-ht2B and 
5-ht2C receptor antagonists. Both substances are ef-
fective but have a high frequency of side effects. nei-
ther is available in Croatia.
pizotifen. Controlled and uncontrolled studies 
have shown that pizotifen is of benefit in 40%-79% of 
patients136,137. Analysis of the placebo controlled trials 
suggested a large clinical effect that was statistically 
significant; in direct comparisons with other agents 
for migraine prevention, no significant differences 
were demonstrated with flunarizine, methysergide, 
or metoprolol138-140. however, in 26 trials reviewed, 
pizotifen was generally poorly tolerated.
The dose recommendation is 0.5-1 mg 1-3 times 
daily by titration105.
Adverse effects: drowsiness, asthenia, increased 
appetite, weight gain. 
Methysergide. four placebo controlled trials sug-
gested that methysergide was significantly better than 
placebo in reducing headache frequency; no differ-
ence was shown in comparison with propranolol and 
pizotifen139,141. The use of methysergide should be re-
stricted to patients who do not respond to other pro-
phylactic treatments, taking carefully into account the 
risk-benefit ratio. The dose ranges from 2 to 8 mg a 
day (maximum 14 mg per day), higher doses given in 
3 times; starting dose is 1 mg and increased by 1 mg 
every 2-3 days. 
Contraindications: pregnancy, severe arteriosclero-
sis, coronary heart disease, severe hypertension, peptic 
ulcer, fibrotic disorders, lung diseases, collagen diseases, 
liver and renal impairment, valvular heart disease. 
Adverse effects: transient muscle aching, claudi-
cation, abdominal distress, nausea, weight gain, hal-
lucinations. Major complications are rare and include 
retroperitoneal, pulmonary and endocardial fibrosis 
(estimated frequency of 1 in 5000 treated patients)137. 
A 4-week drug free interval is recommended after 6 
months of continuous treatment to prevent such com-
plications. 
* pizotifen and methysergide are not available in Croatia.
Anticonvulsants
Anticonvulsant medication is increasingly recom-
mended for migraine prevention because of placebo-
controlled, double blind trials that proved it to be ef-
fective. The majority of these trials refer to valproate 
and topiramate, having shown these drugs to be ef-
fective and well tolerated in migraine prevention and 
suitable for first-line clinical use. on the other hand, 
lamotrigine, oxcarbazepine and vigabatrin have been 
shown ineffective and gabapentin requires further 
evaluation. for the rest of the antiepileptic drugs, no 
data from controlled trials are available113.
Studies with divalproex sodium and sodium val-
proate provided strong and consistent support for 
their efficacy142-144. Divalproex sodium was found to 
be more effective compared with placebo, but not 
significantly different compared with propranolol for 
the prevention of migraine in patients without aura145. 
Starting dose is 250-500 mg in divided doses; the 
dose is slightly increased usually up to 1000 mg daily. 
Baseline liver function studies should be obtained. 
Contraindications: pregnancy – divalproex car-
ries a high risk of congenital abnormality; history 
of pancreatitis, chronic hepatitis, hematologic disor-
ders including thrombocytopenia, pancytopenia and 
bleeding disorders. hyperandrogenism resulting from 
elevated testosterone levels, ovarian cysts and obesity 
are of particular concern in young women with epi-
lepsy who use valproate. 
Adverse effects: nausea, vomiting, gastrointesti-
nal distress, somnolence, asthenia, tremor, alopecia, 
weight gain. Severe adverse reactions such as hepatitis 
or pancreatitis are rare.
topiramate is generally safe and reasonably well 
tolerated for the prevention of migraine in adults114-117. 
topiramate in a range of 25-200 mg was associated 
with 33% reduction in monthly headache rate vs. 8% 
in placebo group; >50% reduction in migraine fre-
quency had 47% of patients in topiramate group (dose 
200 mg in divided doses in 6 weeks) as compared with 
6.7% in placebo group146-149. Starting dose is 25 mg, 
the dose is elevated by 25 mg every 7 days up to a dose 
of 200 mg. 
Adverse effects: weight loss, cognitive dysfunction, 
sedation, dizziness, diarrhea.
gabapentin was effective in several trials. gaba-
pentin 600-1800 mg was effective in a 12-week open 
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label study, and in dose 1800-2400 gabapentin was 
superior to placebo in reducing the frequency of mi-
graine attacks by 50% in about 1/3 of patients. gaba-
pentin was not effective in one placebo-controlled, 
double blind study150,151. in an open-label study, the 
mean number of migraine days/4 weeks was reduced 
from 15.8 to 8.6; furthermore, pain intensity was re-
duced by 25% in 14 (26.9%), by 50% in 29 (55.7%), 
by 75% in 3 (5.7%) patients, and no improvement was 
seen in 6 (11.5%) patients. A significant reduction of 
acute medication use was reported152.
Adverse effects: dizziness, drowsiness.
pregabalin: recent data suggest that pregabalin 
may be a useful alternative prophylaxis for chronic 
migraine153,154. These promising results from open-la-
bel studies should be confirmed in randomized clini-
cal trials.
lamotrigine showed lower efficacy in comparison 
to topiramate and in preventing migraine without 
aura, whereas it was efficacious in the prevention of 
high frequency migraine attacks with aura155-157.
Adverse effects: rash, fatigue, dizziness, headache, 
Stevens-Johnson syndrome, toxic epidermal necroly-
sis and hypersensitivity reactions. 
levetiracetam seems to be a safe and effective 
treatment for migraine with aura at a dosage of 1000 
mg/d for 6 months and in elderly patients; however, 
in the prevention of chronic daily headache levetirac-
etem was not as effective158-160. Controlled trials are 
needed to confirm the observed results. 
*All listed medications are available in Croatia but are 
not covered by the Croatian institute of health insur-
ance for migraine prophylaxis and can be purchased with 
a prescription. 
non-steroidal anti-inflammatory drugs (nSAiDs)
The main mechanism of action of non-steroidal 
anti-inflammatory drugs (nSAiDs) is the inhibition 
of cyclooxygenase in both isoforms, whereas, even 
in the absence of inflammation, nSAiDs are active 
in reduction of migraine pain. Some nSAiDs show 
discrete effectiveness in migraine prophylaxis; these 
include acetylsalicylic acid, flurbiprofen, ketoprofen; 
naproxen and naproxen sodium are, however, useful in 
the prevention of menstrual migraine161-165. nSAiDs 
should be used for intermittent prophylaxis in men-
strual migraine, not for prolonged periods of time be-
cause of their gastric side effects. 
Placebo response in prophylactic therapy
A meta-analysis to evaluate the placebo response 
rate in migraine prophylaxis in all clinical trials pub-
lished since 1988 was performed; the pooled estimate 
of the placebo response (patients who improved) was 
21%. The placebo response rates were significantly 
higher in studies with a parallel design than those 
in cross-over studies (p<0.01). This response was also 
higher in european studies than in those performed 
in north America (p<0.001). Adverse events occurred 
in 30% of the patients who took a placebo, and the 
percentage of patients with adverse events was signifi-
cantly higher in the north American studies than in 
those conducted in europe (p<0.01). These data re-
inforce the need to consider the placebo effect when 
ascertaining the true therapeutic effect of any drug, as 
well as to design any clinical trial in the prophylaxis 
of migraine166.
complementary drugs
Although a wide range of acute and preventive 
medications are now available for the treatment of 
migraine headaches, many patients will not have sig-
nificant improvement in the frequency and severity 
of their headaches unless lifestyle modifications are 
made. Also, given the number of side effects of tradi-
tional prescription medications, there is an increasing 
demand for “natural” treatment like vitamins and sup-
plements for the treatment of headaches. The identifi-
cation of food triggers, with the help of food diaries, is 
an inexpensive way to reduce migraine headaches. The 
following supplements in the preventive treatment of 
migraine have been evaluated: magnesium, Petasites 
hybridus, feverfew, coenzyme Q10, riboflavin, and 
ginkgolide167-169. 
Vitamin B2 (riboflavin) 
A recent open-label and a randomized, placebo-
controlled study have found daily supplements of ri-
boflavin 400 mg to be moderately effective in reducing 
the frequency and severity of migraine170,171. however, 
riboflavin is not available in most countries in such 
high doses. 
Riboflavin 25 mg showed an effect comparable to 
a combination of riboflavin 400 mg, magnesium 300 
mg and feverfew 100 mg; the placebo response ex-
ceeded that reported for any other placebo in trials of 
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migraine prophylaxis, and suggests that riboflavin 25 
mg may be an active comparator172. however, there is 
at present conflicting scientific evidence with regard 
to the efficacy of these compounds for migraine pro-
phylaxis.
Adverse effects: mild abdominal pain and diar-
rhea. 
Feverfew 
This herbal therapy is made from crushed chry-
santhemum leaves; 250 micrograms of the active in-
gredient, parthenolide, is considered necessary for 
therapeutic effectiveness. feverfew is considered an 
anti-inflammatory medication with serotonin effects. 
The role of feverfew in migraine prophylaxis is not well 
established. Despite studies showing superiority to pla-
cebo, there is insufficient evidence from randomized, 
double-blind trials to suggest an effect of feverfew over 
and above placebo for preventing migraine173-175. 
A recent study has shown that feverfew is efficient 
in acute treatment of migraine attacks; sublingual fe-
verfew/ginger appears safe and effective as a first-line 
abortive treatment for a population of migraineurs 
who frequently experience mild headache prior to the 
onset of moderate to severe headache176. The efficacy 
of feverfew was not confirmed in a Cochrane review, 
probably because of the 400% variations in the dosage 
of its active principle.
magnesium 
low magnesium certainly is a fundamental mech-
anism of neuronal excitability; migraine patients have 
lower circulating magnesium levels than normal. 
Studies with p-spectroscopy revealed consistent and 
profound changes in posterior brain regions of pa-
tients with hemiplegic migraine and spectroscopic 
images of family members showed low magnesium 
levels. Regarding these observations, supplementing 
magnesium would make sense. Daily oral dosages of 
400 to 600 mg have been shown to be of benefit in 
migraine prevention177-180.
Magnesium sulfate has been shown to be efficient 
in acute migraine treatment: in the migraine with aura 
group patients receiving magnesium sulfate presented 
a statistically significant improvement of pain and of 
all associated symptoms compared with controls181. 
coenzyme Q-10
Magnetic resonance spectroscopy studies and 
DnA analysis suggest that migraine at least in a sub-
set of individuals may be the result of mitochondrial 
impairment. on this basis, coenzyme Q-10 (CoQ10) 
could be used as a preventive treatment for migraine. 
in one open-label study migraine patients were 
treated with 150 mg daily of coenzyme Q-10; by the 
end of 3 months there was a 55% reduction in the fre-
quency of migraine; no side effects were noted182. in 
a randomized, double-blind controlled trial, CoQ10 
(3x100 mg/day) was compared to placebo in 42 mi-
graine patients and CoQ10 was superior to placebo 
for attack frequency, headache days and days-with-
nausea in the third treatment month and was well 
tolerated183.
ginkgolide B, a herbal constituent extract from 
Ginkgo biloba tree leaves, was evaluated in a multi-
center, open, preliminary trial in the prophylactic 
treatment of migraine with aura; ginkgolide B was 
shown to be effective in reducing migraine with aura 
frequency and duration184. 
*All complementary drugs are available in Croatia and can 
be purchased as otC drugs
other therapy
Certain forms of treatment listed below show 
promising results in clinical trials but their use is still 
not recommended. 
Botulinum toxin 
Botulinum toxin significantly reduces the fre-
quency, severity and disability associated with mi-
graine headaches; efficacy was good and consistent 
through studies185-189. Several retrospective open label 
chart reviews and double-blind, placebo-controlled 
studies have demonstrated the efficacy of botulinum 
toxin type A in migraine prophylaxis. The results of 
pReeMpt 2 demonstrate that onabotulinumtoxinA 
is effective for prophylaxis of headache in adults with 
chronic migraine. Repeated onabotulinumtoxinA 
treatments were safe and well tolerated190. onabotu-
linumtoxinA was effective for chronic migraine and 
well tolerated, but the therapeutic gain over placebo 
was modest; the clinical profile of responders remains 
to be determined before widespread use40. 
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onabotulinumtoxinA and topiramate demonstrat-
ed similar efficacy for subjects with chronic migraine; 
overall, the results were statistically significant within 
groups but not between groups191.
The mode of action by which botulinum toxin is 
effective in migraine prophylaxis is not fully under-
stood. Migraine patients with certain characteristic 
features may be given an attempt with botulinum tox-
in for pain relief: muscular stress as migraine trigger, 
concurrent chronic tension-type headache, chronic 
migraine with frequent migraine attacks on more 
than 15 days per month for longer than 3 months, and 
if other therapeutic options have been either ineffec-
tive or have not been tolerated192.
Adverse effects: to date, neither organic damage 
nor allergic complications have been reported and no 
CnS side effects have been noticed.
The tolerability and safety of botulinum toxin type 
A seem to be high. There are a number of ongoing 
clinical trials to evaluate the efficacy, optimal dosing 
and side effect profile of botulinum toxin type A in 
the prophylaxis of migraine and other headache enti-
ties. 
occipital nerve stimulation
occipital nerve stimulation was effective in intrac-
table chronic migraine with 39% of responders com-
pared to 6% after sham stimulation40. 
hyperbaric and normobaric oxygen therapy 
(hBoT, nBoT)
A double-blind, placebo-controlled study in which 
the treatment group received 100% oxygen during 30 
minutes on 3 consecutive days (the control group re-
ceived air) showed a nonsignificant reduction in hours 
of headache per week; the authors concluded that the 
tested protocol did not show a prophylactic effect on 
migraine193. however, hBo showed significant effect 
in acute migraine attacks194,195. 
Randomized trials comparing hBot or nBot 
with one another, other active therapies, placebo 
(sham) interventions or no treatment in patients with 
migraine or cluster headache showed that there was 
some evidence that hBot was effective for termina-
tion of acute migraine in an unselected population, 
and weak evidence that nBot was similarly effective 
in cluster headache. given the cost and poor avail-
ability of hBot, more research should be done in 
patients unresponsive to standard therapy. nBot is 
inexpensive, safe and easy to apply, so it will probably 
continue to be used despite the limited evidence in 
this review196.
Antipsychotic drugs
olanzapine (thienobenzodiazepine) may be effec-
tive for patients with refractory headache who have 
not responded to other prophylactic agents. An open-
label study with olanzapine in daily doses of 2.5 mg 
to 35 mg during 3 months resulted in a significant de-
crease in the number of headache days and headache 
severity. olanzapine may be considered in patients 
with refractory headaches who have mania, bipolar 
disorder or psychotic depression197.
haloperidol iv. is very effective in relieving mi-
graine-associated pain; significant pain relief was 
achieved in 80% of patients treated with haloperidol, 
whereas only 3 (15%) patients responded to placebo 
(p<0.0001)198.
Why treatment fails 
treatment of acute attacks or prophylactic treat-
ment of migraine may fail because of the follow-
ing199:
1. Diagnosis is incomplete or incorrect
 a) an undiagnosed secondary headache disorder is 
present
 b) a primary headache disorder is misdiagnosed 
 c) two or more different headache disorders are 
present
2. important exacerbating factors may have been 
missed 
a) medication overuse (including otC) 
b) caffeine overuse
3. Dietary or lifestyle triggers 
4. hormonal triggers
5. psychosocial factors
6. other medications that trigger headaches (phar-
macotherapy has been inappropriate)
7. ineffective drug; at least 3 attacks should be treat-
ed before deciding that a drug is ineffective
8. inadequate initial doses (low, excessive)
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  9. inadequate duration of treatment 
10. unrealistic expectations
11. Comorbid conditions complicate therapy 
12. inpatient treatment required
13. inadequate formulation or route of administration
14. There is an analgesic abuse
non-pharmacologic treatments include:
Behavioral treatments 
it is extremely difficult to design studies with 
matching placebo, since double blind is impossible, 
thus the majority of studies compared active treat-
ments vs. control group including patients in an out-
patient setting (mostly prospective, controlled “ran-
domized” studies)200,201.
A) relaxation training
Relaxation training includes progressive muscular 
relaxation, autogenic training, breathing exercises, 
and directed imagery. patients learn to control muscle 
tension, to use mental relaxation and/or visual imag-
ery to achieve treatment goals. The goal is to develop 
long-term skills rather than to treat individual events. 
Repetitive sessions and practice by the patient increase 
the successfulness of these therapies in reducing head-
ache frequency. patients need to be motivated and to 
appreciate the potential long-term benefits of this type 
of therapy. it may be especially beneficial for patients 
who cannot take prophylactic medication or who have 
been unsuccessful with prophylactic pharmacological 
treatment202,203.
B) Psychotherapy
Cognitive behavioral therapy is based on the 
premise that anxiety and distress aggravate an evolv-
ing migraine, and has the potential of helping the pa-
tient recognize maladaptive responses that may trig-
ger headache. Cognitive-behavioral training (stress 
management training) teaches skills for identifying 
and controlling stress and minimizing the effects of 
stress204.
c) Biofeedback therapy
1) thermal biofeedback (tBR) (hand warming) – 
teaching the patient to warm the hands (vasodila-
tation) by using rapid sensory feedback
2) electromyographic (eMg) biofeedback training. 
The results obtained with eMg biofeedback and 
tBR have shown that neither technique is superior. 
The mean headache improvement when eMg bio-
feedback was applied using the headache index was 
23%-51%; positive and negative results were achieved 
for tBR. however, a combination of tBR and eMg 
biofeedback yielded the best results205,206. Thermal 
biofeedback associated with relaxation techniques has 
been recommended as a first-choice nonpharmaco-
logical treatment for migraine, and physical therapy 
has been indicated as a second-choice treatment for 
migraineurs who do not sufficiently improve with 
tBR207. A study where patients were randomly as-
signed to receive biofeedback in addition to the basic 
relaxation instruction or relaxation techniques alone 
and received instruction in pain theory showed that 
biofeedback provided no additional benefit when 
compared to simple relaxation techniques alone, in 
the treatment of migraine and tension type head-
aches in adults208. however, a meta-analysis of papers 
on biofeedback showed that the main results were 
medium-to-large mean effect sizes for biofeedback in 
adult migraine and tension-type headache patients. 
treatment effects remained stable over an average 
follow-up period of 14 months, both in completer and 
intention-to-treat analyses. headache frequency was 
the primary outcome variable and showed the largest 
improvements. further significant effects were shown 
for perceived self-efficacy, symptoms of anxiety and 
depression, and medication consumption. Reduced 
muscle tension in pain related areas was observed in 
eMg feedback for tension-type headache. Biofeed-
back was more effective than waiting list and head-
ache monitoring conditions in all cases, while eMg 
feedback for tension-type headache showed additional 
significant effects over placebo and relaxation thera-
pies. levels of efficacy (migraine: efficacious, level 4; 
tension-type headache: efficacious and specific, level 
5)209. 
d) hypnosis
hypnosis has a long tradition but a few controlled 
studies are available regarding its effectiveness in mi-
graine treatment. in considering the possibility of 
combining hypnosis with other nonpharmacologi-
cal therapies, a meta-analysis of a broad number of 
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controlled studies suggested that hypnosis could be of 
benefit in the treatment of headache when combined 
with cognitive-behavioral therapy210.
Physical treatment
A few noninvasive physical treatments may be ef-
fective as prophylactic treatments for chronic/recur-
rent headaches. The randomized controlled trials sug-
gest that massage therapy, physiotherapy, relaxation 
and chiropractic spinal manipulative therapy might 
be as effective as propranolol and topiramate in the 
prophylactic management of migraine. for the pro-
phylactic treatment of migraine headache, there is 
evidence that spinal manipulation may be an effec-
tive treatment option with a short-term effect similar 
to that of a commonly used, effective drug (amitrip-
tyline). other possible treatment options with weaker 
evidence of effectiveness are pulsating electromagnetic 
fields and a combination of transcutaneous electrical 
nerve stimulation (tenS) and electrical neurotrans-
mitter modulation. for the prophylactic treatment of 
chronic tension-type headache, amitriptyline is more 
effective than spinal manipulation during treatment. 
however, spinal manipulation is superior in the short 
term after cessation of both treatments. other possible 
treatment options with weaker evidence of effective-
ness are therapeutic touch; cranial electrotherapy; a 
combination of tenS and electrical neurotransmitter 
modulation; and a regimen of auto-massage, tenS, 
and stretching. for episodic tension-type headache, 
there is evidence that adding spinal manipulation to 
massage is not effective. Based on trial results, these 
treatments appear to be associated with a little risk of 
serious adverse effects. however, the evaluated ran-
domized controlled trials had many methodological 
shortcomings. 
The clinical effectiveness and cost-effectiveness of 
noninvasive physical treatments require well-conduct-
ed randomized controlled trials of manual therapies 
for migraine211,212.
A) Acupuncture
Acupuncture has been used both to prevent and 
treat diseases for over 3000 years. Controlled studies 
specifically applied to migraine have produced mixed 
findings and positive studies had some methodologi-
cal doubts213. treatment outcomes for migraine do not 
differ between patients treated with sham acupuncture, 
verum acupuncture, or standard therapy214,215. howev-
er, a Cochrane review on its use in migraine concludes 
that acupuncture is effective and should be considered 
as a prophylactic measure for patients with frequent or 
insufficiently controlled migraine attacks216.
B) cervical manipulation
Cervical mobilization (movement of a joint within 
the normal range of movement) and cervical manipu-
lation (movement of a joint beyond its normal range 
of oscillation) provided little advantage for the use of 
these techniques in patients with migraine. previous 
studies suggested potentially high levels of risk as-
sociated with improper application of this modality. 
Although more recent studies report few complica-
tions, there is well documented evidence for cerebral 
infarction and death from cervical manipulation. The 
scientific evidence is not convincing to show signifi-
cant benefits217,218. 
c) Transcutaneous electrical nerve stimulation 
(Tens)
tenS units for migraine or muscle contraction 
headache have not been found to be more beneficial 
than placebo when evaluated in a controlled study.
d) massage, homeopathy and naturopathy
Massage, homeopathy and naturopathy have been 
found to be without supporting evidence.
Recommendation for nonpharmacological treatment: 
1. Relaxation training, thermal biofeedback com-
bined with relaxation training, electromyographic 
biofeedback and cognitive-behavioral therapy may 
be considered as treatment options for prevention 
of migraine (level A). Specific recommendations 
regarding which of these to use in specific patients 
cannot be made.
2. Behavioral therapy (relaxation, biofeedback) may 
be combined with preventive drug therapy (pro-
pranolol, amitriptyline) to achieve additional clin-
ical improvement for migraine relief (level B).
3. evidence-based treatment recommendations are 
not yet possible for hyponosis, acupuncture, tran-
Acta Clin Croat,  Vol. 51,  No. 3,  2012 353
vlasta vuković Cvetković et al. evidence based guidelines for treatment of primary headaches – 2012 update
scutaneous electrical nerve stimulation, chiroprac-
tic or osteopathic cervical manipulation, and hy-
perbaric oxygen (level C).
menstrual migraine 
The definition of menstrual migraine has been 
proposed in the appendix of ihS: pure menstrual 
migraine without aura, menstrually-related migraine 
without aura and non-menstrual migraine without 
aura23. Menstrually related migraine (MRM) head-
ache is common in women and associated with sub-
stantial disability. Clinical experience suggests that 
menstrual migraine attacks are more severe, longer in 
duration, and more difficult to treat than migraine at-
tacks at other times of the month219, 220. iron deficien-
cy anemia may play a role in the severity of migraine, 
particularly menstrual migraine220. 
Diagnosis of menstrual migraine should be con-
firmed with calendar record. The provider and patient 
need to discuss diary documentation. The patient 
should keep continuous daily record for at least 2 
months to include the following:
•	 day/time of headache 
•	 severity of headache 
•	 duration 
•	 onset of menstrual flow
Screening tests in women with migraine prior to 
use of combined oral contraceptives (CoCs):
no specific tests need to be undertaken other than 
those routinely performed or indicated by the patient’s 
history or the presence of specific symptoms221.
Migraine-related symptoms that may necessitate 
further evaluation and/or cessation of CoCs:
•	 new persisting headache
•	 new onset of migraine aura
•	 increased headache frequency or intensity
•	 development of unusual aura symptoms, particu-
larly prolonged aura
Treatment of menstrual migraine – cyclic 
prophylaxis
Acute attacks of menstrual migraine should be 
treated as usual. prophylactic treatment includes 
nSAiDs, triptans and hormonal prophylaxis222-228:
nSAiDs should be considered first-choice ap-
proaches in the prophylactic treatment of migraine 
associated with menses. naproxen sodium 550 mg 
twice a day (bid) has been used as a preventive agent. 
other nSAiDs may also be effective 3-7 days before 
menstruation until 1-7 days after. typically, the agent 
is initiated two to three days before the anticipated 
onset of headache and continued through the at-risk 
period. Based on the evidence, grade B recommenda-
tions can be made for the use of sumatriptan 50 and 
100 mg, mefenamic acid 500 mg, frovatriptan 2.5 mg 
twice daily, naratriptan 1 mg twice daily and rizatrip-
tan 10 mg for the acute treatment of MRM.
oral contraceptives have a variable effect on mi-
graines, causing worsening of headaches in some pa-
tients, improvement of headaches in a small percent-
age of patients, and no change in migraines in other 
patients. estrogen levels decrease during the late luteal 
phase of the menstrual cycle, likely triggering mi-
graine. estrogen replacement prior to menstruation 
has been used to prevent migraine.
estradiol patches are applied 48 hours prior to the 
expected onset of migraine and used daily for the next 
7 days; it is the treatment of choice in women taking 
CoCs since the expected date of attack is precisely 
known. A relatively high dose of this hormone (1.5 
mg per day) may be efficacious since low doses such as 
50 mcg per day are not as efficacious (grade B recom-
mendations).
Choosing among treatment strategies must be 
based on clinical considerations. Contraceptive strat-
egies offer the opportunity for treating menstrual mi-
graine in women who also require effective contracep-
tion.
migraine and menopause
During perimenopause, it is likely to observe wors-
ening of migraine, and tailored hormonal replacement 
therapy (hRt) to minimize estrogen/progesterone 
imbalance may be effective. Although migraine prev-
alence decreases with advancing age, migraine can 
either regress or worsen at menopause. Women with 
prior migraine generally improve with physiological 
menopause; in contrast, surgical menopause usually 
results in worsening of migraine229-231.
Treatment of hormonal replacement headache 
in the treatment of hormonal replacement head-
ache try the following:
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estrogens
•	 reduce estrogen dose
•	 change estrogen type from conjugated estrogen to 
pure estradiol to synthetic estrogen or to pure es-
trone
•	 convert from interrupted to continuous dosing
•	 convert from oral to parenteral dosing
•	 add androgens
•	 switch to selective estrogen receptor modulator
progestin
•	 switch from interrupted (cyclic) to continuous 
lower dose
•	 change progestin type
•	 change delivery system (vaginal)
•	 discontinue progestin
Migraine and risk of stroke in women using CoCs 
or hRt 
A systematic review and meta-analysis of migraine 
and cardiovascular disease has shown that migraine is 
associated with a twofold increased risk of ischemic 
stroke, which is only apparent among people who 
have migraine with aura. The results also suggest a 
higher risk among women and the risk was further 
magnified in people with migraine who were aged less 
than 45, smokers, and women who used oral contra-
ceptives. There has not been found an overall asso-
ciation between any migraine and myocardial infarc-
tion or death due to cardiovascular disease. too few 
studies are available to reliably evaluate the impact of 
modifying factors, such as migraine aura, on these as-
sociations232. Studies also show that CoC users with 
a history of migraine are two to four times as likely to 
have an ischemic stroke as nonusers with a history of 
migraine. The odds ratios for ischemic stroke ranged 
from 6 to almost 14 for CoC users with migraine 
compared with nonusers without migraine233.
There is no contraindication to the use of CoCs in 
women with migraine in the absence of migraine aura 
or other risk factors. Women should be counseled and 
regularly assessed for the development of additional 
risk factors. Currently, the usual indications and con-
traindications for hRt should be applied. in certain 
cases, CoCs may be contraindicated. it appears rea-
sonable that women who have prolonged migraine au-
ras (certainly those beyond 60 minutes), multiple aura 
symptoms, or less common aura symptoms (e.g., dys-
phasia, hemiparesis) should be strongly discouraged 
from using estrogen-containing oral contraceptives 
(oCps). patients who develop a migraine aura for the 
first time while taking estrogen-containing oCps, or 
whose previous typical migraine aura becomes more 
prolonged or complex, should discontinue estrogen-
containing oCps (level C). The decision should be 
individualized and should be made with the patient.
A quantitative systematic review on patent fora-
men ovale (pfo) and migraine showed that the as-
sociation between migraine and pfo was oR 2.54 
(95% Ci 2.01, 3.08). Although pfo closure seemed 
to affect migraine patterns favorably, the very low 
grade of available evidence to support this association 
precludes definitive conclusions234. 
practical management:
•	 diagnose migraine type, particularly the presence 
of aura
•	 identify and evaluate risk factors
•	 risk factors such as hypertension and hyperlipi-
demia should be treated
•	 women with migraine who smoke should stop 
smoking before starting CoCs
•	 consider non-ethinyl estradiol methods in women 
who are at an increased risk of ischemic stroke, 
particularly those who have multiple risk factors. 
observational studies suggest that progesterone-
only hormonal contraceptive use is not associated 
with an increased risk of ischemic stroke, although 
quantifiable data are limited
Additional risk factors for ischemic stroke in wom-
en with migraine using CoCs:
•	 age >35 years
•	 ischemic heart disease or cardiac disease with em-
bolic potential
•	 diabetes mellitus
•	 family history of arterial disease <45 years
•	 hyperlipidemia
•	 hypertension
•	 migraine aura
•	 obesity (body mass index >30)
•	 smoking
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•	 systemic disease associated with stroke (connective 
tissue disorders)
migraine and pregnancy
A recent study has shown that there is no clear evi-
dence for the increased risks of preterm delivery and 
its subtypes with isolated migraine disorder. Women 
with mood disorder had elevated risks of pre-eclamp-
sia (adjusted RR=3.57, 95% Ci 1.83, 6.99). our results 
suggest an association between isolated migraine dis-
order and pregnancy-induced hypertension (adjusted 
RR=1.42, 95% Ci 1.00, 2.01)235.
Most women with migraine improve during preg-
nancy; however, some women have their first attack 
during pregnancy236-238. Migraine often recurs during 
postpartum and can begin for the first time in gen-
eral. Migraine treatment is often necessary because 
maternal and fetal risks related to acute attacks may 
be more harmful than the therapy itself, especially if 
they are frequent, severe and associated with nausea, 
anorexia, vomiting, hypotension or dehydration. The 
major concern in managing the pregnant migraineur 
is the effect of both medication and migraine on the 
fetus. Since migraine usually improves after the first 
trimester, many women can manage their headaches 
with this reassurance along with nonpharmacological 
means and it should be preferred. Some women con-
tinue to have severe headaches that may not only be 
disruptive to the patient, but they pose a risk to the fe-
tus that is greater than the potential risk of the medi-
cations used to treat the pregnant patient. Because of 
the possible risk of injury to the fetus, medication use 
should be limited; however, it is not contraindicated 
during pregnancy. 
Among nonpharmacological migraine prophy-
laxis, only relaxation techniques, biofeedback in par-
ticular, and acupuncture have accumulated sufficient 
evidence in support of their efficacy and safety. Some 
vitamins and dietary supplements have been proposed: 
the prophylactic properties of magnesium, riboflavin 
and coenzyme Q10 are probably low, but their lack 
of severe adverse effects makes them good treatment 
options239. 
paracetamol and nSAiDs should be preferred for 
the treatment of acute migraine attacks in pregnant 
women. Migraine prophylaxis should be undertaken 
when patients experience at least three prolonged se-
vere attacks a month that are particularly incapacitat-
ing or unresponsive to symptomatic therapy and likely 
to result in complications. if nonpharmacological ap-
proaches are not effective, preventive treatment should 
include low doses of β-blockers and amitriptyline240.
Caution – aspirin in low intermittent doses is not 
associated with a significant teratogenic risk, although 
large doses, especially near term, may be associated 
with maternal and fetal bleeding.
to avoid: ergotamine, Dhe, triptans, barbitu-
rates, benzodiazepines.
nausea: promethazine, prochlorperazine supposi-
tories.
Severe attacks of migraine should be treated ag-
gressively; intravenous fluids should be administered 
for hydration and in conjunction with prochlorpera-
zine iv. to control both nausea and pain. 
Principles of migraine management: clinical 
highlights
1. Migraine is diagnosed by history and physical ex-
amination with limited need for imaging or labo-
ratory tests. 
2. Consider additional testing if necessary. 
3. Acute migraine therapy should be started with 
non-opioid analgesics (with or without antiemet-
ics) the earliest possible in the attack. Adequate 
dosage should be administered; keep in mind 
that the dosage is higher than the usual analge-
sic/antipyretic dose. Appropriate pharmacological 
or analgesic treatment of acute migraine should 
generally not exceed >2 days per week on a regular 
basis. More than this may result in chronic daily 
headaches. 
4. Consider triptans if nSAR fails. 
5. Consider which patients require prophylactic 
therapy. Depending on comorbid disease, beta 
blockers, antidepressants or anticonvulsants are 
first-line therapy to be introduced. Most prophy-
lactic medications should be started in a low dose, 
titrated to a therapeutic dose to minimize side ef-
fects and maintained at target dose for at least 12 
weeks to assess efficacy. 
6. Migraines occurring in association with menses 
and not responsive to standard cyclic prophylaxis 
may respond to hormonal prophylaxis with the use 
of estradiol patches or oral contraceptives. 
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7. Additional lifestyle modifications or risk factor 
avoidance should be discussed. 
2. tension-type headache (tth)
previously used terms: psychomyogenic headache, 
stress headache, muscle contraction headache, ordi-
nary headache, essential headache
This is the most common type of primary head-
ache; lifetime prevalence in the general population 
ranges in different studies from 30% to 80%241. A 
population-based study in Croatia has estimated the 
1-year age- and sex-adjusted prevalence of tth to 
be 20.7%12. 
in the general population, 4%-5% of individuals 
suffer from chronic daily headache and about half of 
them have chronic tension-type headache (Ctth) 
with more than 15 headaches per month242. 
frequent episodic and chronic tth is caused by 
a combination of genetic and environmental factors, 
while infrequent episodic tth is caused primarily 
by environmental factors243. The pathophysiology of 
Ctth is unknown; it has been suggested that in-
creased myofascial tenderness and muscle hardness 
play an important role, although evidence for a cen-
trally mediated origin of Ctth is increasing244-246. 
increased pericranial tenderness recorded by manual 
palpation is the most significant abnormal finding in 
patients with tth. The tenderness increases with 
the intensity and frequency of headache. Studies on 
the exteroceptive suppression of temporal muscle con-
traction have detected a dysfunction of the brainstem 
excitability and of its suprasegmental control. A simi-
lar conclusion has been reached by using the trigemi-
nocervical reflexes, whose abnormalities in tth have 
suggested a reduced inhibitory activity of brainstem 
interneurons, reflecting abnormal endogenous pain 
control mechanisms. it is interesting that the neu-
ral excitability abnormality in tth seems to be a 
generalized phenomenon, not limited to the cranial 
districts. it has been demonstrated that continuous 
nociceptive input from peripheral myofascial struc-
tures may induce central sensitization and thereby 
chronification of the headache. Measurements of pain 
tolerance thresholds and suprathreshold stimulation 
have shown the presence of generalized hyperalgesia 
in Ctth patients247,248.
Diagnostic criteria for tension type headache are 
as follows2:
2.1 infrequent episodic tension-type headache 
(etth) – diagnostic criteria
A. At least 10 previous headache episodes occurring 
on <1 day per month on average (<12 days per year) 
and fulfilling criteria B-D 
B. headache lasting from 30 minutes to 7 days 
C. At least 2 of the following characteristics: 
pressing/tightening (nonpulsating) quality 
Mild or moderate intensity (may inhibit but does not 
prohibit activities) 
Bilateral location
4. no aggravation by routine physical activity such as 
walking or climbing stairs 
D. Both of the following:
1. no nausea or vomiting (anorexia may occur) 
2. photophobia and phonophobia are absent, or 
one but not the other is present
e. not attributed to another disorder
2.1.1 infrequent episodic tension-type headache asso-
ciated with pericranial tenderness
A. episodes fulfilling criteria A-e for 2.1 infrequent 
episodic tension-type headache
B. increased pericranial tenderness on manual palpa-
tion
2.1.2 infrequent episodic tension-type headache not 
associated with pericranial tenderness
A. episodes fulfilling criteria A-e for 2.1. infrequent 
episodic tension-type headache
B. no increased pericranial tenderness on manual 
palpation
2.2 frequent episodic tension-type headache – 
diagnostic criteria
A. At least 10 previous headache episodes occurring 
on ≥1 day but <15 days per month for at least 3 
months (>12 and <180 days per year) and fulfilling 
criteria B-D
B, C, D, E as in 2.1. 
Comment:
•	 frequent tension-type headache often coexists 
with migraine without aura, these two types of 
headache should be distinguished best by a diag-
nostic headache diary in order to select the right 
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treatment and to prevent from medication-overuse 
headache
2.2.1 frequent episodic tension-type headache associ-
ated with pericranial tenderness
A. episodes fulfilling criteria A-e for 2.2. frequent 
episodic tension-type headache
B. increased pericranial tenderness on manual palpa-
tion
2.2.2 frequent episodic tension-type headache not as-
sociated with pericranial tenderness
A. episodes fulfilling criteria A-e for 2.2. frequent 
episodic tension-type headache
B. no increased pericranial tenderness on manual 
palpation
2.3 Chronic tension-type headache (Ctth) – diag-
nostic criteria
A. Average headache frequency >15 days/month for 
>3 months (>180 days/year), fulfilling criteria B-D
B. headache lasts for hours or may be continuous 
C. At least 2 of the following characteristics: 
1. pressing/tightening quality
2. Mild or moderate severity (may inhibit but does 
not prohibit activities)
3. Bilateral location
4. no aggravation by walking stairs or similar rou-
tine physical activity
D. Both of the following: 
1. no more than one of photophobia, phonophobia or 
mild nausea
2. neither moderate nor severe nausea or vomiting
e. not attributed to another disorder
2.3.1 Chronic tension-type headache associated with 
pericranial tenderness
A. headache fulfilling criteria A-e for 2.3. Chronic 
tension-type headache
B. increased pericranial tenderness on manual palpa-
tion
2.3.2 Chronic tension-type headache not associated 
with pericranial tenderness
A. headache fulfilling criteria A-e for 2.3. Chronic 
tension-type headache
B. no increased pericranial tenderness on manual 
palpation
2.4 probable tension-type headache – diagnostic cri-
teria
2.4.1 probable infrequent tension-type headache
A. episodes fulfilling all but one of criteria A-D for 
2.1. infrequent episodic tension-type headache
B. episodes do not fulfill criteria for 1.1. Migraine 
without aura
C. not attributed to another disorder
2.4.2 probable frequent tension-type headache
A. episodes fulfilling all but one of criteria A-D for 
2.2. frequent episodic tension-type headache
B. episodes do not fulfill criteria for 1.1. Migraine 
without aura
C. not attributed to another disorder
2.4.3 probable frequent tension-type headache
A, B, C, D as in 2.3.
e. not attributed to another disorder but there is, 
or has been within the last 2 months, medication 
overuse fulfilling criterion B for any of the sub-
forms of 8.2 Medication-overuse headache
Diagnosis
There is no laboratory test that will make the di-
agnosis; underlying structural or metabolic disease 
should be considered when evaluating a patient who 
fulfills the diagnostic criteria of tth.
neuroimaging is unlikely to reveal an abnormality 
on MRi or Ct scanning in patients with tension-type 
headache and normal neurological examination6.
Recommendation: data are insufficient to make an 
evidence-based recommendation regarding the use of 
neuroimaging for tension-type headache.
Therapy
treatment of tension-type headache is mostly un-
satisfactory and includes physical therapy, simple an-
algesics or antidepressant drugs247,248. The vast major-
ity of people with tension-type headache take simple 
analgesics or no medicine at all; people may seek help 
if tth episodes occur with unusual frequency or in-
tensity. 
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i Acute treatment
Simple analgesics and nSAiDs are recommended 
for the treatment of episodic tth. Combination 
analgesics containing caffeine are drugs of second 
choice. triptans, muscle relaxants and opioids should 
not be used. it is crucial to avoid frequent and exces-
sive use of analgesics to prevent the development of 
medication-overuse headache249.
As a general rule, medications used for an acute 
headache should be taken at a relatively high dose and 
as early as possible5.
1) Analgesics 
a) paracetamol 500-1000 mg
b) aspirin 500-1000 mg
2) nsAids
a) diclofenac 50-100 mg
b) ketoprofen 25-50 mg
c) naproxen 500-750 mg
d) ibuprofen 400-800 mg
3) combination drugs (see migraine-acute therapy)
* The majority of nSAiDs and non-opioid analgesics are 
available in Croatia, some of them are partially covered by 
the Croatian institute of health insurance, a prescription 
is usually needed.
ii Preventive treatment
Although tth typically is not as disabling as mi-
graine, its chronic form may significantly impair the 
patients’ functional ability. Most preventive agents 
used for primary tth have not been examined in 
well-designed double-blind studies. The tricyclic anti-
depressant amitriptyline is the drug of first choice for 
prophylactic treatment of chronic tth. Mirtazapine 
and venlafaxine are drugs of second choice. over-
all, evidence for the efficacy of different antiepileptic 
drugs in chronic headache forms and in chronic head-
ache is still lacking, most studies being open-label, 
small-sample trials123,128,249,250.
Pharmacological treatment
Antidepressants 
Antidepressants are most commonly used since 
many patients have comorbid depression and anxi-
ety. in an open label study in non-depressed patients 
with either etth or Ctth, amitriptyline 25 mg/
day significantly reduced analgesic consumption and 
the frequency and duration of headache in Ctth but 
not in etth251. The tricyclic antidepressant amitrip-
tyline is the drug of first choice for prophylactic treat-
ment of chronic tth. Mirtazapine and venlafaxine 
are second-choice drugs249,252.
* Amitriptyline is available in Croatia, covered by the Croa-
tian institute of health insurance (100%), a prescription is 
needed. fluoxetine is available in Croatia, covered by the 
Croatian institute of health insurance (partial), a prescrip-
tion is needed.
Anticonvulsants 
Anticonvulsants represent a therapeutic option for 
chronic daily headache; studies evaluating gabapen-
tin, topiramate, sodium valproate and levetiracetam 
have been conducted160,253-256.
Botulinum toxin
Botulinum toxin was shown to affect the release 
of neurotransmitters that are important in pain trans-
mission and in migraine pathogenesis. Data from 
both animal and clinical studies suggest that the toxin 
may have an analgesic effect that is independent from 
its effect on muscle tone. t he high tolerability and 
long duration of action of the drug make it appeal-
ing as a potential prophylactic treatment for headache 
patients. Results of controlled trials on the efficacy of 
botulinum toxin in the treatment of episodic migraine 
are mostly negative, although some subgroups of pa-
tients (e.g., those with high attack frequency) may re-
spond to the drug. Studies of patients with chronic 
daily headache have been inconclusive, although (as 
with the episodic migraine studies) specific subgroups 
of patients appear to benefit from the drug. Botuli-
num toxin is probably ineffective for the treatment of 
chronic tth257,258. 
Most of the initial reports on botulinum toxin in 
tth and in migraine were positive. unfortunately, 
these results were not reproduced in well-designed, 
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randomized controlled trials. So far, doses from 20 
u (Botox) to 500 u (Dysport) have been studied in 
patients with chronic tth, and doses from 16 to 200 
u (Botox) in patients with migraine. overall, there is 
no evidence for a beneficial effect of botulinum toxin, 
although trends favoring botulinum toxin have been 
reported. experience with botulinum toxin type B 
(Myobloc/neuroBloc) is limited and similar to the 
experience with type A. Thus, a widespread use of 
botulinum toxin therapy in headache can currently 
not be recommended259-264.
* Botulinum toxin is available in Croatia, not covered by 
the Croatian institute of health insurance for the treat-
ment of tension type headaches and should not be given in 
the preventive approach for headache management.
nonpharmacological treatment 
non-drug management should always be con-
sidered, although the scientific basis is limited. in-
formation, reassurance and identification of trigger 
factors may be rewarding. electromyography (eMg) 
biofeedback has a documented effect in tth, whilst 
cognitive-behavioral therapy and relaxation training 
most likely are effective. physical therapy and acu-
puncture may be valuable options for patients with 
frequent tth, but there is no scientific evidence for 
efficacy249. Cochrane review on the use of acupuncture 
in tth concludes that it could be a valuable non-
pharmacological tool in patients with frequent epi-
sodic or chronic tths265. 
a) teaching healthy habits with regard to sleep, 
meals, exercise and eliminating unhealthy habits 
such as smoking and drinking 
b) psychological and behavioral techniques (see Mi-
graine nonpharmacological treatment)
3. cLUsTer heAdAche And 
oTher TriGeminAL AUTonomic 
cePhALALGiAs
trigeminal-autonomic cephalalgias (tACs) are 
primary headaches characterized by short-lasting, 
unilateral, severe attacks of headache and accompa-
nying typical cranial autonomic symptoms. 
According to the second edition of the hiS classi-
fication, the following syndromes belong to tACs: 3.1 
episodic and chronic cluster headache; 3.2 episodic 
and chronic paroxysmal hemicrania; 3.3 SunCt; 
and 3.4 probable tACs3. 
3.1 cluster headache
previously used terms: horton’s headache, hor-
ton’s neuralgia, migrainous neuralgia, hemicrania 
neuralgiformis chronica, ciliary neuralgia, histaminic 
cephalalgia, erythromelalgia of the head.
Cluster headache (Ch) is characterized by attacks 
of severe, strictly unilateral pain, located orbitally, 
supraorbitally, temporally or combined but may be 
spread to other regions of the head; the attacks are 
accompanied by autonomic features on the pain side. 
Most patients are restless or agitated during the at-
tack. Attacks usually occur in series (cluster periods) 
lasting for weeks and months or years. pain almost 
invariably recurs on the same side during an individu-
al cluster period. About 15% of patients have chronic 
symptoms without remissions longer than 30 days. 
Conversion to a chronic form seems to be related to 
the occurrence of more than one cluster period a year 
and the short-lived duration of remission periods, lon-
ger duration of the disease and to a late age at onset266. 
A single cluster period has been described in 27% of 
patients267. During the cluster period, attacks may be 
provoked by alcohol (not during remision periods), 
histamine or nitroglycerine, or sudden variation in 
temeperature. Cluster periods usually last between 2 
weeks and 3 months. The frequency of attacks varies 
between one every other day and two a day, the dura-
tion of attacks is about 30 to 120 minutes (minimum 
15, maximum 180 minutes). The individual attacks 
show a defined temporal profile, they often occur with 
‘clock-like’ regularity; cluster periods often begin in 
spring and autumn (268). The usual age at onset is in 
the 20s to 40s, and is older in chronic than in episodic 
Ch; the prevalence is 5-6 times higher in men than in 
women. The pooled data showed a lifetime prevalence 
of 124 per 100,000 and a 1-year prevalence of 53 per 
100,000269. 
Studies suggest that there is an increased familial 
risk of Ch, the mechanism of which remains to be 
fully elucidated. Ch is inherited in only a minority 
of cases with an autosomal dominant pattern, and it 
seems that Ch results from the interaction of more 
than one gene (polygenic inheritence). epidemio-
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logical studies found an increased prevalence among 
Ch patients with cigarette smoking, previous head 
trauma (but not head trauma associated with loss of 
consciousness) and family history of headache. Acute 
attacks involve activation of the posterior hypotha-
lamic grey matter.
The diagnosis of Ch is mainly based on accurate 
description of the headache and associated headache 
symptoms; neurophysiological tests are not warranted 
in the routine work-up of such patients. Diagnostic 
criteria for cluster headache are as follows:
A. At least 5 attacks fulfilling criteria B-D
B. Severe or very severe unilateral orbital, supraorbital 
and/or temporal pain lasting for 15-180 minutes if 
untreatedx
C. headache is accompanied by at least one of the 
following:
 ipsilateral conjunctival injection and/or lacrima-
tion
 ipsilateral nasal congestion and/or rhinorrhea
 ipsilateral eyelid edema
 ipsilateral forehead and facial sweating
 ipsilateral miosis and/or ptosis
 a sense of restlessness or agitation
D. Attacks have a frequency from one every other day 
to 8 per dayxx
e. not attributed to another disorderxxx
note:
xDuring part (but less than half) of the time-course 
of cluster headache, attacks may be less severe and/or 
of shorter or longer duration.
xxDuring part (but less than half) of the time-
course of cluster headache, attacks may be less fre-
quent.
xxxhistory and physical and neurological exami-
nations do not suggest any of the disorders listed in 
groups 5-12, or history and/or physical and/or neu-
rological examinations do suggest such a disorder but 
it is ruled out by appropriate investigations, or such a 
disorder is present but attacks do not occur for the first 
time in close temporal relation to the disorder.
3.1.1 Episodic cluster headache
Diagnostic criteria:
A. Attacks fulfilling criteria A-e for 3.1 Cluster 
headache
B. At least two cluster periods lasting for 7-365 daysx 
and separated by pain-free remission periods of ≥1 
month
note:
xCluster periods usually last between 2 weeks and 
3 months.
3.1.2 Chronic cluster headache
Diagnostic criteria:
A. Attacks fulfilling criteria A-e for 3.1 Cluster 
headache
B. Attacks recur over >1 year without remission peri-
ods or with remission periods lasting <1 month
Comment:
Chronic cluster headache may arise de novo (pre-
viously referred to as primary chronic cluster head-
ache) or evolve from the episodic subtype (previously 
referred to as secondary chronic cluster headache). 
Some patients may switch from chronic to episodic 
cluster headache.
TherAPy
i Acute treatment
in all cases, patients should be instructed to avoid 
afternoon naps and alcohol drinks, alcohol may in-
duce acute attacks during active cluster periods. pa-
tients should be cautioned about prolonged exposure 
to certain substances such as solvents, gasoline or 
oil-based paints during cluster periods. Altitude hy-
poxemia may induce attacks during cluster periods. 
Bursts of anger, prolonged anticipatory anxiety and 
excessive physical activity should be avoided because 
cluster attacks are apt to occur during the relaxation 
period that follows.
Triptans
Sumatriptan. Three clinical trials, controlled versus 
placebo, were investigating the efficacy of sumatriptan 
in acute cluster headache attacks. Subcutaneous su-
matriptan 6 mg was tested in two studies270, 271, sub-
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cutaneous sumatriptan 12 mg in one271, and intranasal 
sumatriptan 20 mg in one study272.
Subcutaneous sumatriptan is well tolerated and 
effective even when taken frequently during a cluster 
period. The recommended dose is 6 mg (level A). in-
tranasal sumatriptan in a dosage of 20 mg appears to be 
less effective than subctaneous formulation, and not to 
have rapid onset of action as the latter one (level B).
Zolmitriptan. The efficacy of zolmitriptan in clus-
ter headache was investaigated in three controlled 
versus placebo studies. oral zolmitriptan 5 mg and 
10 mg doses were tested in one study273, and intrana-
sal zolmitriptan 5 mg and 10 mg doses in two stud-
ies274,275.
oral zolmitriptan in a single dosage of 10 mg has 
proved its efficacy only in episodic cluster headache 
attacks (level B). intranasal zolmitriptan may have 
comparable clinical efficacy to that of sumatriptan 
(level A).
oxygen
two randomized controlled studies have investi-
gated 100% oxygen versus placebo for the acute treat-
ment of cluster headache276,277. The results showed the 
inhalation ofoxygen at a rate of 6-12 l/min in sitting 
position for at least 15 minutes was effective treatment 
for acute cluster headache attacks in the majority of 
patients (level A). unlike triptans, oxygen does not 
have major adverse events, is well tolerated and there 
is no limitation to the number of times per day it can 
be used. oxygen therapy for cluster headache should 
be used with caution in patients with chronic obstruc-
tive pulmonary disease.
There was a trend to better outcome in a single 
trial evaluating hyperbaric oxygen therapy (hBot) 
for termination of cluster headache. hBot may be 
considered for breaking the cluster cycle in refractory 
cluster headache patients, although the majority of 
cluster headache patients would not benefit any sus-
tained effect (level C).
dihydroergotamine and ergot derivatives
The role of ergot alcaloids in the acute treatment of 
cluster headache is limited. Combinations of ergotamine 
and caffeine failed do demonstrate clinical efficiency 
in acute cluster headache attacks. only one placebo 
controlled study showed clinical benefit of intranasal 
Dhe (0.5 mg per spray per nostril) in the treatment of 
acute cluster headache. intranasal Dhe decreased the 
intensity but not the duration of the attacks, and was 
well tolerated (level B) (278). in an open retrospective 
trial, the intravenous application of 1 mg Dhe over 3 
days has been shown to be effective for termination of 
refractory cluster attacks (level C)279. ergots may have 
serious adverse effects and are contraindicated in pa-
tients with cardiovascular diseases; they cannot be used 
simuntaneously with triptans.
Lidocaine
Based on the results from several noncontrolled 
studies and 1 randomized controlled trial, intranasal 
lidocaine (1 ml solution with a concentration of 4%) 
is moderately effective in the treatment of acute clus-
ter headache attacks (level B)280,281. it should be used 
as adjunctive therapy when patients do not respond to 
more effective therapies.
octreotide
in a placebo controlled trial, octreotide, a soma-
tostatin analog, in a dose of 100 μg sc. has been shown 
to be effective in the treatment of acute cluster head-
ache attacks (level B)282. it has no vasocnostrictor ef-
fect and could be used in patients with contraindica-
tions to triptans.
Drugs level of evidence
Clinical 
effectiveness
triptans A +++
Sumatriptan sc. B +
Sumatriptan in* A +
Zolmitriptan in* B ?
Zolmitriptan po. A ++
oxygen inhalation A ++
ergots
Dhe in* B ?
Dhe iv. C ++
lidocaine in* B +
octreotide sc. B +
* in = intranasal
Table 6. Evidence for acute medication in cluster headache 
attacks
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olanzapine
olanzapine was given as an abortive agent (2.5 to 
10 mg) to five patients with cluster headache in only 
one open-label trial283.
evidence for acute medication in acute cluster 
headache attacks are listed in table 6.
to treat acute attacks, try the following:
1. oxygen inhalation at a flow rate of 6-7 l/min for 
at least 15 minutes
2. Sumatriptan 6 mg sc. (if available) or 20 mg nasal 
spray
3. Zolmitriptan 5-10 mg nasal spray (if available) or 
5-10 mg po.*
4. Dhe 1 mg nasal spray (if available) or 1 mg iv.
5. lidocaine 4% sol intranasal
Alternatively
6. octreotide 100 μg sc.**
*po. only for episodic cluster
**only if steps 2-5 are contraindicated
ii Preventive treatment
The objectives of prophylactic therapy are aimed 
at reducing the frequency, severity and duration of at-
tacks and consequently to end the cluster phase.
The principles of phrophylactic therapy are:
– Begin treatment early, particularly in the episodic 
forms
– Continue treatment for at least 10 to 14 days after 
the disapperance of the crisis
– gradually suspend treatment
– if the crisis reappears, increase dosages to thera-
peutic levels
The drug choice depends on different factors:
– Age and lifestyle of the patient
– expected duration of the cluster phase
– type of cluster headache (episodic or chronic)
– Response to previous treatments
– possible reported side effects
– Contraindications to the use of the drug
– Comorbid pathologies
Pharmacological treatment
calcium channel blockers
verapamil is considered the first-choice drug for 
prophylactic treatment of cluster headache, both the 
episodic and chronic forms. There are 2 placebo con-
trolled trials investigating the use of verapamil as a 
prophylactic drug for cluster headache (level B). 
During 2 weeks of treatment, 80% of patients receiv-
ing verapamil had a greater than 50% reduction in 
headache frequency284. Most patients will respond to 
doses of 240 mg to 480 mg per day divided in three 
doses. Both immediate and extended release formula-
tions may be used. to reduce side effects (hypoten-
sion, constipation, and peripheral edema), start with 
low initial dose (120 mg daily) and slowly taper up 
to the target dose. eCg monitoring is recomended 
during verapamil therapy because of the risk of heart 
block and bradycardia. verapamil may be combined 
with corticosteroids, triptans and other prophylactic 
agents.
corticosteroids
Corticosteroids are often prescribed as initial pro-
phylactic drug, in order to obtain rapid relief of cluster 
attacks. They induce remission in most severe cases 
with high attack frequency and pain intensity, par-
ticularly in the central phase of the cluster period. in 
several open studies, both oral and parenteral corticos-
teroids provided benefit in cluster headache patients.
prednisone is used at doses of 50-60 mg per day for 
2-3 days, then decresasing the dose by 10 mg per day 
every 2-3 days. The treatment period should not ex-
ceed 3 weeks. headache may reappear when the dose 
is less than 25 mg/day; in this case, another long-act-
ing prophylactic drug may be added along with pred-
nisone. Despite the fact that there are no adequate 
randomized, placebo-controlled trials available on the 
use of prednisone in cluster headache, prednisone is 
considered as a clinically effective prophylactic agent 
(level C).
A single high dose of intravenous methyl predni-
solone in most patients with episodic cluster headache 
may interrupt attack recurrence for a few days, but is 
ineffective in maintaining complete clinical remission. 
it does not provide any advantage above prednisone in 
cluster headache treatment285. 
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in an open study, dexamethasone administered 
parenterally at a dose of 4 mg bid for 2 weeks followed 
by 4 mg a day in the 3rd week was able to interrupt the 
cluster period286. 
Suboccipital corticosteroid injection. There are 
two placebo controlled studies investigating suboc-
cipital corticosteroid injections in cluster headache 
(level B). A total of 85% of patients in the study 
group had relief of cluster headache attacks by 72 
hours after single application of betamethasone di-
propionate and betamethasone disodium phosphate 
with Xylocaine 2%, compared to 0% of patients in 
the placebo group. This effect was maintained for at 
least 4 weeks in the majority of them287. in another 
study, patients who received cortivazol also had fewer 
attacks in the first 15 days of the study than controls 
irrespective of the cluster headache type (chronic or 
episodic)288. 
Lithium
lithium carbonate is considered to be effective in 
the prophylaxis of both episodic and chronic cluster 
as much as verapamil289. however, lithium should 
be administered as a second choice of prophylactic 
therapy for chronic cluster (level C) because of its 
side effects (tremor, diarrhea, mental confusion), the 
need for blood test monitoring during therapy, and its 
potential for drug interactions with SSRis, thiazide 
diuretics, indomethacin and diclofenac.
The initial dose is 300 mg, which should be in-
creased to 900 mg per day (maximum dose is 1200 mg 
per day). Serum doses should be measured 12 hours af-
ter the last dosage and should not exceed 1.2 mmol/l 
(effective serum concentration 0.6 to 0.8 mmol/l). 
Thyroid and renal functional parameters should be 
checked before and during treatment.
serotonin antagonists
Methysergide. A review of observational stud-
ies published in 1967 found that methysergide was 
an effective preventive drug for 73% of people with 
episodic cluster headache290. however, later studies 
found that effieciency ranged from 20% to 30%291. 
prolonged treatment with methysergide has been as-
sociated with rare fibrotic reactions (retroperitoneal, 
pulmonary, pleural, and cardiac). Therefore, methy-
sergide should be administired for the prophylaxis of 
episodic cluster headache no longer the 3 months in a 
dosage of 8-12 mg per day (level C).
pizotifen. in a small, single-blind, non-random-
ized, crossover-design controlled trial in patients with 
episodic cluster headache, pizotifen significantly re-
duced the number of headache attacks, duration and 
severity compared with placebo292. it should be ad-
ministered only in case of refractory episodic cluster, 
when other therapies fail (level C). The recommend-
ed daily dosage is 1.5 mg, taken in 3 divided doses or 
as a single dose before sleep.
Anticonvulsants
valproate. in open and retrospective studies, val-
proate has been shown to be effective for prophylaxis 
of cluster headache293,294. however, one double-blind 
placebo-controlled study of sodium valproate did not 
support its efficacy due to an unexpectedly high re-
sponse rate in the placebo group295. The recommended 
daily dosage ranges from 500 to 2000 mg in 2 divided 
doses.
topiramate. observational studies have found that 
topiramate may be effective in about 50% of people 
with cluster headache296,297. placebo controlled studies 
with longer treatment periods are required to establish 
the efficacy of topiramate for the prevention of cluster 
headache. The recommended daily dosage is 50 to 200 
mg in 2 divided doses. The adverse effects associated 
with topiramate use include paresthesia, fatigue, an-
orexia, nausea, and cognitive impairment.
gabapentin. open studies showed clinical benefit 
of gabapentin in patients treated for chronic or refrac-
tory cluster headache298,299. The recommended doses 
range from 800 mg to 3600 mg per day. Common 
adverse events include somnolence and fatigue, dizzi-
ness, weight gain, peripheral edema, and ataxia.
other agents
Melatonin. There is 1 placebo-controlled trial that 
investigated melatonin 10 mg daily in prophylaxis of 
cluster headache (level C).There was a reduction in 
daily headache frequency in the melatonin group but 
not in the placebo group300. however, melatonin failed 
to produce any additional benefit as adjunctive therapy 
in patients with refractory cluster headache301. 
Dihydroergotamine. Dhe administered intra-
venously was demonstrated to induce rapid dissa-
364 Acta Clin Croat,  Vol. 51,   No. 3,  2012
vlasta vuković Cvetković et al. evidence based guidelines for treatment of primary headaches – 2012 update
pearence of cluster attacks when administered daily 
(0.5-0.8 mg in 8 h)302. it is useful for refractory cluster 
headache, is more effective for the episodic form than 
the chronic form, and has a rapid onset of action. it 
did not change the evolution of the episodic form, but 
it did appear to induce remission in the chronic form 
or transform it to the episodic form303. 
ergotamine tartrate. oral ergotamine tartrate 
is recommended for short-term prophylaxis (up to 4 
weeks) of nocturnal attacks. The recommended dose 
is 1-2 mg taken before sleep.
Capsaicin. in a double-blind study, capsaicin at a 
concentration of 0.025% applied 2 times per day for 7 
days into the ipsilateral nostril was shown to be more 
effective than placebo in reducing the frequency and 
severity of the crises304. long-term use of capsaicin 
is inappropriate because of the unpleasant local reac-
tions induced by the drug.
Civamide. in a small double blind study, intrana-
sal civamide solution at a dose of 50 μg may be mod-
estly effective in the preventive treatment of episodic 
cluster headache305. 
Clonidine applied as 7.5 mg transdermal patch 
was studied in 2 small open-label studies306,307. in the 
first one, there were significant reductions in the at-
tack frequency, pain intensity, and attack duration of 
cluster headache. on the other hand, the second study 
failed to confirm its clinical benefit.
in the prophylactic therapy of cluster headache try 
the following:
1. verapamil 3x80 mg per day to 3x120 
 mg, max. 480 mg per day.
2. prednisone 50-60 mg for 3-5 days, 
followed by 10 mg decrements over 
3 days up to 3 weeks or dexametha-
sone 4 mg bid for 2 weeks followed 
by 4 mg per day for 1 week.
3. lithium carbonate 300 mg tid or 
450 mg sustained release if chronic 
cluster headache. note: litium has 
narrow therapeutic window. The 
serum concentration should be mea-
sured 12 hours after the last dose 
and should not exceed 1.0 mmol/l. 
4. topiramate 50 mg to 200 mg per 
day divided in 2 doses.
5. Dhe administered intravenously for refractory 
cluster headache or ergotamine tartrate 1-2 mg per 
os before sleep for nocturnal attacks.
evidence for prophylactic medication in cluster 
headache is listed in table 7.
nonpharmacological treatment
refractory patients
Approximately 10% of patients develop chronic 
cluster headache which does not respond to mono-
therapy. in patients with chronic headache, surgical 
treatment may be the only alternative therapy when 
medical therapy is ineffective, is limited by contrain-
dications, or is poorly tolerated308. 
The following criteria should be applied in carefully 
selected patients:
1) total resistance to pharmacolagical treatment (se-
vere side effects and contraindicitaions to therapy)
2) headache strictly located on the same side
3) pain primarily in the region of the ophthalmic 
branch of the trigeminal nerve
4) patients with stable personality and psychological 
profile with little tendency to somatization.
options:
neuromodulation 
Chronic occipital nerve stimulation through a 
subcutaneous occipital electrode connected to an im-
Drugs level of 
evidence
Clinical ef-
fectiveness
Comment
verapamil po. B +++ first choice for both episodic and chronic Ch
prednisone po. C +++
initial prophylaxis 
th. combined with 
maintenance drugs
lithium po. C +++ Chronic Ch
Suboccipital 
corticosteroid B ++
Both episodic and chronic 
Ch
Methysergide po. C + episodic Ch up to 3 months
pizotifen po. C ? Refractory episodic Ch
Melatonin po. C ?
Table 7. Evidence for prophylactic medication in cluster headache (CH)
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planted generator, in order to induce paresthesias per-
ceived locally in the lower occipital region. The mean 
attack frequency and intensity decreased by 68% and 
49%, respectively309.  
in observational studies, hypothalamic deep brain 
stimulation has been proved to successfully prevent 
attacks in more than 60% of 58 hypothalamic im-
planted drug-resistant chronic cluster headache pa-
tients. The implantation procedure has generally been 
proved to be safe, although it carries a small risk of 
brain hemorrhage310. Randomized phase findings of a 
randomized placebo-controlled double-blind trial did 
not support the efficacy of deep brain stimulation in 
refractory chronic cluster headache311.
stereotactic radiosurgery
gamma knife surgery for intractable, medically 
refractory cluster headache provided lasting pain re-
duction in approximately 60% of patients, but was as-
sociated with a significantly greater chance of facial 
sensory disturbances than gamma knife surgery used 
for trigeminal neuralgia312.
Ablative surgical procedures in trigeminal region
The procedures that appear to be more effective in 
the long-term management of the disease are radiof-
requency trigeminal ganglion ablation and trigeminal 
rhizotomy313,314. There is strong evidence that even 
complete trigeminal denervation is not effective in 
preventing attacks or autonomic symptoms of refrac-
tory chronic cluster headache315. 
3.2 Paroxysmal hemicrania
Some features of paroxysmal headache attacks, the 
pain character and associated autonomic symptoms 
may resemble those observed in cluster headache. 
however, the attacks are of shorter duration and more 
frequent, more related to female sex and terminated 
by use of indomethacin. There is an episodic and a 
chronic form of paroxysmal hemicrania with the fol-
lowing diagnostic criteria:
A. At least 20 attacks fulfilling criteria B-D
B. Attacks of severe unilateral orbital, supraorbital or 
temporal pain lasting for 2-30 min
C. headache is accompanied by at least one of the 
following:
1. ipsilateral conjunctival injection and/or lacrima-
tion
2. ipsilateral nasal congestion and/or rhinorrhea
3. ipsilateral eyelid edema
4. ipsilateral forehead and facial sweating
5. ipsilateral miosis and/or ptosis
D. Attacks have a frequency above 5 per day for more 
than half the time, although periods with lower 
frequency may occur
e. Attacks are prevented completely by therapeutic 
doses of indomethacin
f. not attributed to another disorder
3.2.1 Episodic form
Diagnostic criteria:
A. Attacks fulfilling criteria A-f for 3.2 Paroxysmal 
hemicrania
B. At least two attack periods lasting for 7-365 days 
and separated by pain-free remission periods of ≥1 
month
3.2.2 Chronic form
Diagnostic criteria:
A. Attacks fulfilling criteria A-f for 3.2 Paroxysmal 
hemicrania
B. Attacks recur over >1 year without remission peri-
ods or with remission periods lasting <1 month
indomethacin in daily doses of 150 mg up to 200 
mg is the first choice for the treatment of paroxysmal 
hemicrania (level A). if not tolerated, verapamil or 
other nSAiDs may be substituted. 
3.3  short-lasting unilateral neuralgiform 
headache attacks with conjunctival injection and 
tearing (sUncT)
SunCt syndrome is very rare in the general pop-
ulation and its real prevalence is unclear. it is more 
frequent in female sex (male/female ratio is 1:4). This 
syndrome is characterized by short-lasting attacks of 
unilateral pain that are much briefer than any of those 
seen in other trigeminal autonomic cephalalgias. At-
tacks are very often accompanied by autonomic symp-
toms of the ipsilateral eye (lacrimation and redness); 
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although other cranial autonomic symptoms such as 
nasal congestion, rhinorrhea or eyelid edema may oc-
cur (in the latter cases, the proper description term is 
short-lasting unilateral neuralgiform headache attacks 
with cranial autonomic symptoms (SunA)). 
The differential diagnosis to the classical trigemi-
nal neuralgia may be difficult, but autonomic symp-
toms are not prominent and triggered attacks have a 
clear refractory period 
Diagnostic criteria:
A. At least five attacks fulfilling criteria B-D
B. Attacks of unilateral orbital, supraorbital or tempo-
ral stabbing or pulsating pain lasting for 5-240 s
C. pain is accompanied by ipsilateral conjunctival in-
jection and lacrimation
D. Attacks occur with a frequency of 3 to 200 per 
day
e. not attributed to another disorder 
until recently, there was no consistently effective 
treatment known for SunCt syndrome lamotrigi-
ne in initial dose of 25 mg/day and gradually titrated 
to higher daily dose is the treatment of choice for 
SunCt (level C). lamotrigine appears to decrease 
the frequency and severity of SunCt attacks, lead-
ing to complete resolution in some patients316. There 
is a lack of randomized placebo-controlled clinical 
trials evaluating lamotrigine in SunCt syndrome 
therapy. 
Alternative medication options include other anti-
convulsive agents (gabapentin, topiramate or oxcarba-
zepine) or intravenous lidocaine317. in refractory cases, 
these drugs may be applied in combination. 
3.4 Probable trigeminal autonomic cephalalgia
headache attacks that are believed to be a subtype 
of trigeminal autonomic cephalalgia but which do not 
quite meet the diagnostic criteria for any of the sub-
types described under 3.1., 3.2., 3.3.
Diagnostic criteria:
A. Attacks fulfilling all but one of the specific criteria 
for one of the subtypes of trigeminal autonomic 
cephalalgia
B. not attributed to another disorder.
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Appendix
Classification of published studies according to their 
scientific validity in evidence levels (according to the 
criteria of the Agency for health Care policy and Re-
search; perfetto and Morris 1996):
translation of evidence to recommendation:
level A - requires at least one convincing class i 
study or at least two consistent, convin-
cing class ii studies
level B - requires at least one convincing class ii 
study or at least three consistent class iii 
studies
level C - requires at least two convincing and consi-
stent class iii studies
Rating of therapeutic article:
Class iA - evidence based on meta-analysis of rando-
mized and controlled studies
Class iB - evidence based on at least one randomized 
and controlled study
Class ii - evidence based on at least one well desi-
gned controlled study without randomi-
zation
Class iii - evidence based on well-designed, non-
experimental, descriptive studies, for 
example comparison study, correlation 
study or case-control study
Class iv - evidence based on experience of expert 
committees or experts; case reports
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Sažetak
ove su smjernice izrađene kako bi pomogle liječniku u ispravnom odabiru dijagnostičkih i terapijskih postupaka kod 
bolesnika s glavoboljom. glavni cilj ovih Smjernica zasnovanih na dokazima za liječenje primarnih glavobolja – Dopunje-
no izdanje 2012. jest dati preporuke za postavljanje točne dijagnoze i za odabir odgovarajuće terapije u skupini bolesnika s 
primarnim glavoboljama, zasnovane na sveobuhvatnom pregledu i meta-analizi znanstvenih dokaza u odnosu na terapijske 
mogućnosti u hrvatskoj. ovi su podaci utemeljeni na našim prethodnim Smjernicama zasnovanim na dokazima za liječe-
nje primarnih glavobolja objavljenim 2005. godine te na drugim preporukama i smjernicama za liječenje glavobolje. 
Ključne riječi: Migrena; Cluster glavobolja; Liječenje glavobolje; Farmakoterapija
